Page last updated: 2024-11-12

rucaparib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9931954
CHEMBL ID1173055
CHEBI ID134689
CHEBI ID94311
SCHEMBL ID844585
MeSH IDM0585719

Synonyms (68)

Synonym
283173-50-2
rucaparib ,
8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CHEBI:134689 ,
AG-14447 ,
KINOME_3180 ,
CHEMBL1173055
D10079
rucaparib (usan/inn)
8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6h-azepino(5,4,3-cd)indol-6-one
6h-azepino(5,4,3-cd)indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
6h-pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-
rucaparib [usan:inn]
unii-8237f3u7eh
8237f3u7eh ,
NCGC00263173-03
NCGC00263173-01
6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-
8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one
AKOS015898427
bdbm50446130
S4948
BRD-K88560311-011-01-4
rucaparib [inn]
rucaparib [mi]
rucaparib [usan]
rucaparib [who-dd]
HY-10617A
ag14447
gtpl7736
SCHEMBL844585
8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
HMABYWSNWIZPAG-UHFFFAOYSA-N
RPB ,
AC-24390
8-fluoro-2-(4-((methylamino)methyl)phenyl)-4,5-dihydro-1h-azepino[5,4,3-cd]indol-6(3h)-one
FT-0696622
DTXSID10182563 ,
CHEBI:94311
6-fluoro-2-{4-[(methylamino)methyl]phenyl}-3,10-diazatricyclo[6.4.1.0?,(1)(3)]trideca-1,4,6,8(13)-tetraen-9-one
AS-74779
C74459
NCGC00263173-13
c19h18fn3o
rucaparib(ag-014447)
DB12332
6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
BCP07633
rucaparib free base
283173-50-2 (free base)
8-fluor-2-{4-[(methylamino)methyl]fenyl}-1,3,4,5-tetrahydro-6hazepino[5,4,3-cd]indool-6-on
rucaparib; ag 014699; pf-01367338
EX-A2700
Q7376558
SB16538
6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]
NCGC00263173-09
nsc756644
nsc-756644
8-FLUORO-5-(4-((METHYLAMINO)METHYL)PHENYL)-2,3,4,6-TETRAHYDRO-1H-AZEPINO[5,4,3-CD]INDOL-1-ONE
6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.0^{4,13]trideca-1,4,6,8(13)-tetraen-9-one
A856084
dtxcid50105054
l01xx55
rucaparibum
8-fluoro-2-[4-[(methylamino)methyl]phenyl]-4,5-dihydroazepino[5,4,3-cd]indol-6(3h)-one
SY047482
mfcd11977252

Research Excerpts

Overview

Rucaparib is a drug with potential as maintenence monotherapy in ovarian cancers irrespective of genetic mutation. It is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive ovarian cancer (OC)

ExcerptReferenceRelevance
"Rucaparib is a drug with potential as maintenence monotherapy in ovarian cancers irrespective of genetic mutation."( Rucabarib: A new lease of life for ovarian cancer patients.
Rabbani, TK; Sachdeva, S,
)
1.57
"Rucaparib (RCP) is a potent selective inhibitor of both PARP-1 and PARP-2 enzymes that induces synthetic lethality in cancer cells. "( Evaluation of phototoxicity induced by the anticancer drug rucaparib.
Andreu, I; Jiménez, MC; Mateos-Pujante, A, 2022
)
2.41
"Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated with a deleterious BRCA1 or BRCA2 mutation. "( Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Beltman, J; Giordano, H; Harding, TC; Liao, M; Maloney, L; Simmons, AD; Xiao, JJ, 2022
)
2.42
"Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). "( Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
Alarcón, J; Barquín, A; Calzas, J; Casado, V; Constenla, M; Dosil, A; Estévez, P; Fuentes, J; Gaba, L; González-Martín, A; Gutiérrez, M; Herrero, A; Madani, J; Manso, L; Márquez, R; Marquina, G; Merino, M; Pajares, B; Reche, P; Salvador, C; Sánchez, L; Santaballa, A; Taus, Á; Yubero, A, 2022
)
3.61
"Rucaparib (Ruc) is a drug used to treat advanced ovarian cancer associated with deleterious BRCA mutations. "( Rucaparib cocrystal: Improved solubility and bioavailability over camsylate.
Cheng, Y; Dai, W; Jiang, Y; Mei, X; Rong, X; Xia, M; Zhu, B, 2023
)
3.8
"Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. "( PARP Inhibitors for Cancer Therapy.
Kraus, WL; Lin, KY, 2017
)
1.9
"Rucaparib appears to be a safe and effective new option in the treatment of relapsed, advanced BRCA1/2 mutant ovarian cancer. "( Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
Moore, DC; Patel, J; Ringley, JT, 2019
)
3.4
"Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. "( Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Coleman, RL; Dal Molin, GZ; Westin, SN, 2018
)
3.37
"Rucaparib is a potent, orally available, small-molecule inhibitor of poly ADP-ribose polymerase (PARP) 1 and 2. "( Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Beijnen, JH; Durmus, S; Schinkel, AH; Sparidans, RW; van Esch, A; Wagenaar, E, 2015
)
2.06
"Rucaparib is an orally available potent selective small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) 1 and 2. "( Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Acton, G; Backholer, Z; Boddy, A; Curtin, N; Drew, Y; Glasspool, R; Halford, S; Hall, G; Highley, M; Jamieson, D; Jayson, G; Ledermann, J; Mangano, R; Murray, J; Plummer, R; Rea, D; Sludden, J, 2016
)
2.08
"Rucaparib is a potent Poly (ADP-ribose) Polymerase (PARP) inhibitor currently under clinical development. "( PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Curtin, NJ; Kern, KA; Kirkpatrick, TR; Li, C; Plummer, R; Sam, WJ; Shalinsky, DR; Sun, W; Wang, DD; Zhang, S, 2015
)
2.05
"Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc. "( Rucaparib: First Global Approval.
Syed, YY, 2017
)
3.34

Effects

ExcerptReferenceRelevance
"Rucaparib has a manageable safety profile; the most common adverse events reported were fatigue and nausea in both indications."( Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Beltman, J; Giordano, H; Harding, TC; Liao, M; Maloney, L; Simmons, AD; Xiao, JJ, 2022
)
1.7
"Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. "( A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data.
Chen, J; Ding, Y; Shu, Y; Zhang, Q, 2023
)
2.61

Treatment

Rucaparib maintenance treatment provided clinically meaningful efficacy benefits across subgroups based on response to last platinum-based chemotherapy or baseline disease. RUCAParib significantly improved progression-free survival versus placebo.

ExcerptReferenceRelevance
"Rucaparib maintenance treatment provided clinically meaningful efficacy benefits across subgroups based on response to last platinum-based chemotherapy or baseline disease."( Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Aghajanian, C; Amenedo Gancedo, M; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI, 2021
)
2.36
"Rucaparib maintenance treatment significantly improved progression-free survival versus placebo irrespective of progression-free interval following penultimate platinum, number of lines of prior chemotherapy, and previous use of bevacizumab."( Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Aghajanian, C; Amenedo Gancedo, M; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI, 2021
)
3.51

Toxicity

We focus on rucaparib's pharmacology, key clinical trials that support its current indication, the competitive landscape, and our considerations for management of adverse events. Grade 3/4 adverse events occurred in 46% (17/37) of patients, with one grade 4 adverse event (anemia) and no deaths. The most frequent treatment-emergent adverse event was anaemia or decreased haemoglobin.

ExcerptReferenceRelevance
" In the safety population (n=377), the most frequent treatment-emergent adverse events (AEs) were nausea, asthenia/fatigue, vomiting, and anemia/hemoglobin decreased."( Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Bell-McGuinn, K; Brenton, JD; Castro, CM; Chen, LM; Coleman, RL; Giordano, H; Goble, S; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Raponi, M; Ray-Coquard, I; Rolfe, L; Shapira-Frommer, R; Sun, J; Swisher, EM; Tinker, AV, 2017
)
0.71
" The most frequent treatment-emergent adverse event of grade 3 or higher was anaemia or decreased haemoglobin (80 [22%] patients in the rucaparib group vs one [1%] patient in the placebo group)."( Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Aghajanian, C; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI, 2020
)
2.2
" We review the safety profile of rucaparib in both settings and provide recommendations for the clinical management of the main adverse events (AEs) that may occur during rucaparib treatment."( Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.
García-Donas, J; Joly, F; Lorusso, D; Sehouli, J, 2020
)
1.11
"The exposure-response analyses provide support for the approved starting dose of rucaparib 600 mg BID for maximum clinical benefit with subsequent dose modification only following the occurrence of a treatment-emergent adverse event in patients with BRCA-mutated recurrent ovarian carcinoma."( Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Aghajanian, C; Beltman, J; Brenton, JD; Castro, C; Chen, LM; Coleman, RL; Goble, S; Green, M; Harding, T; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Ray-Coquard, I; Shapira-Frommer, R; Simmons, AD; Swisher, EM; Tinker, AV; Xiao, JJ, 2021
)
1.09
" Most frequent any-grade treatment-emergent adverse events were asthenia/fatigue (57."( Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Adra, N; Alva, A; Chowdhury, S; Dusek, RL; Feyerabend, S; Grande, E; Grivas, P; Gupta, S; Josephs, DH; Loehr, A; Loriot, Y; Morales-Barrera, R; Necchi, A; Nepert, D; Rodriguez-Vida, A; Simmons, A; Srinivas, S; Teo, MY; Thomas, D; Vogelzang, NJ; Wride, K; Zakharia, Y, 2021
)
0.93
" Outcomes of interest included: serious adverse event (SAE), discontinuation due to adverse event (AE), interruption of treatment due to AE, dose reduction due to AE, and specific grade 1-5 AEs."( Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
Cai, Z; Cao, D; Chang, C; Jiang, Z; Liu, C; Mu, M; Shen, C; Yin, X; Yin, Y; Zhang, B; Zhang, L; Zhao, Z, 2021
)
0.62
" The results obtained are highly relevant concerning RCP photosafety and become clinically important in the context of identification of the cutaneous adverse events that can be associated with the targeted therapies."( Evaluation of phototoxicity induced by the anticancer drug rucaparib.
Andreu, I; Jiménez, MC; Mateos-Pujante, A, 2022
)
0.96
"We focus on rucaparib's pharmacology, key clinical trials that support its current indication, the competitive landscape, and our considerations for management of adverse events."( The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management.
Antonarakis, ES; Rao, A, 2022
)
1.42
" The median time to onset of the most common nonhaematological treatment-emergent adverse events (TEAEs) was typically early (<56 days) and was later for haematological TEAEs (53-84 days)."( Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Balmaña, J; Banerjee, S; Borrow, J; Burris, HA; Chen, LM; Domchek, SM; Drew, Y; Glasspool, RM; Goble, S; Kristeleit, RS; Lin, KK; Maloney, L; Oza, AM; Patel, MR; Safra, T; Shapira-Frommer, R, 2023
)
1.22
" Grade 3/4 adverse events occurred in 46% (17/37) of patients, with one grade 4 adverse event (anemia, deemed related to rucaparib) and no deaths."( A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Barve, M; Bracarda, S; Carles, J; de Braud, F; Fang, B; Gallo, JD; Geynisman, DM; Gurney, H; Harris, A; Huang, KC; Joshua, AM; Kerloeguen, Y; Kim, M; Llácer Pérez, C; Maruzzo, M; Maund, SL; Pérez-Gracia, JL; Pook, D; Poon, V; Shin, SJ; Sutaria, DS, 2023
)
1.34

Pharmacokinetics

A population pharmacokinetic analysis of rucaparib revealed no effect of age, sex, race, or body weight. The plasma concentration-time profiles of rUCAParib in combination with bevacizumab suggest no pharmacokinetics interactions between the drugs.

ExcerptReferenceRelevance
"Although the concept of a phase 0 trial is a relatively new one, there has been a slowly increasing trend toward basing early clinical trial designs on pharmacokinetic and pharmacodynamic end points that has been developing over many years."( The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert, AH; Plummer, R, 2008
)
0.35
" No substantial difference in pharmacokinetic parameters was found between the cohorts or in the pharmacokinetic profiles of rucaparib administered alone or with bevacizumab with respect to historical controls."( Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Ceruti, T; Cresta, S; D'Incalci, M; de Braud, F; Giolitto, S; Lorusso, D; Maltese, G; Matteo, C; Raspagliesi, F; Ronzulli, D; Sabatucci, I; Sinno, V; Sonetto, C; Zucchetti, M, 2021
)
1.17
" The plasma concentration-time profiles of rucaparib in combination with bevacizumab suggest no pharmacokinetic interactions between the drugs."( Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Ceruti, T; Cresta, S; D'Incalci, M; de Braud, F; Giolitto, S; Lorusso, D; Maltese, G; Matteo, C; Raspagliesi, F; Ronzulli, D; Sabatucci, I; Sinno, V; Sonetto, C; Zucchetti, M, 2021
)
1.22
" Pharmacokinetic parameters were compared between hepatic function groups, and safety and tolerability were assessed."( Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Beltman, J; Centkowski, P; Drew, Y; Dziadziuszko, R; Grechko, N; Habeck, J; Liao, M; Nash, E; Ramlau, R; Skarbova, V; Tomaszewska-Kiecana, M; Xiao, J; Zemanova, M, 2021
)
0.91
" A population pharmacokinetic analysis of rucaparib revealed no effect of age, sex, race, or body weight."( Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Beltman, J; Giordano, H; Harding, TC; Liao, M; Maloney, L; Simmons, AD; Xiao, JJ, 2022
)
1.24

Compound-Compound Interactions

Oral rucaparib can be safely combined with a clinically relevant dose of carboplatin in patients with advanced solid tumours (Trial registration ID: NCT01009190) The plasma concentration-time profiles of rucAParib in combination with bevacizumab suggest no pharmacokinetic interactions.

ExcerptReferenceRelevance
" The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy."( Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Boddy, A; Calvert, H; Curtin, N; Dewji, R; Evans, J; Harris, A; Johnson, P; Jones, C; McHugh, P; Middleton, M; Newell, D; Olsen, A; Plummer, R; Robson, L; Steinfeldt, H; Wang, D; Wilson, R, 2008
)
0.35
"To observe the effects of poly(ADP-ribose)polymerase (PARP) inhibitor AG014699 alone and combined with docetaxel (DTX) or carboplatin (CBP) on the proliferation of triple-negative breast cancer cell line MDA-MB-231 and to investigate whether PARP inhibitor AG014699 combined with chemotherapy could play a synergistic antitumor effect."( [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
Ding, H; Li, L; Li, XQ; Sun, Y, 2014
)
0.4
"MDA-MB-231 cells were treated by PARP inhibitor AG014699 alone or combination with DTX or CBP."( [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
Ding, H; Li, L; Li, XQ; Sun, Y, 2014
)
0.4
"PARP inhibitor AG014699 combined with DTX or CBP can remarkably inhibit MDA-MB-231 cell proliferation, showing additive or synergistic antitumor effects."( [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
Ding, H; Li, L; Li, XQ; Sun, Y, 2014
)
0.4
"This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours."( A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Dieras, V; Evans, TJ; Giordano, H; Goble, S; Jaw-Tsai, S; Middleton, MR; Molife, LR; Plummer, R; Roxburgh, P; Spicer, J; Wilson, RH, 2017
)
0.94
"Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, or epirubicin/cyclophosphamide."( A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Dieras, V; Evans, TJ; Giordano, H; Goble, S; Jaw-Tsai, S; Middleton, MR; Molife, LR; Plummer, R; Roxburgh, P; Spicer, J; Wilson, RH, 2017
)
0.96
"Oral rucaparib can be safely combined with a clinically relevant dose of carboplatin in patients with advanced solid tumours (Trial registration ID: NCT01009190)."( A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Dieras, V; Evans, TJ; Giordano, H; Goble, S; Jaw-Tsai, S; Middleton, MR; Molife, LR; Plummer, R; Roxburgh, P; Spicer, J; Wilson, RH, 2017
)
1.24
"The phase I portion of MITO 25 was designed to determine the maximum tolerated dose, pharmacokinetics, and the safety profile of rucaparib when administered in combination with bevacizumab as maintenance treatment for patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer."( Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Ceruti, T; Cresta, S; D'Incalci, M; de Braud, F; Giolitto, S; Lorusso, D; Maltese, G; Matteo, C; Raspagliesi, F; Ronzulli, D; Sabatucci, I; Sinno, V; Sonetto, C; Zucchetti, M, 2021
)
1.17
" Because these dose-limiting toxicities occurred in the 600-mg group and affected more than one in three patients, the maximum tolerated dose for rucaparib was considered 500 mg twice daily when combined with bevacizumab 15 mg/kg at day 1 every 21 days."( Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Ceruti, T; Cresta, S; D'Incalci, M; de Braud, F; Giolitto, S; Lorusso, D; Maltese, G; Matteo, C; Raspagliesi, F; Ronzulli, D; Sabatucci, I; Sinno, V; Sonetto, C; Zucchetti, M, 2021
)
1.16
" The plasma concentration-time profiles of rucaparib in combination with bevacizumab suggest no pharmacokinetic interactions between the drugs."( Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Ceruti, T; Cresta, S; D'Incalci, M; de Braud, F; Giolitto, S; Lorusso, D; Maltese, G; Matteo, C; Raspagliesi, F; Ronzulli, D; Sabatucci, I; Sinno, V; Sonetto, C; Zucchetti, M, 2021
)
1.22

Bioavailability

Rucaparib has moderate oral bioavailability and can be dosed with or without food. A high-fat meal slightly increased bioavailability at 600 mg but not at lower doses.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Compound 34 is orally bioavailable and displayed favorable pharmacokinetic (PK) properties."( Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
Ahirrao, P; Bakhle, D; Bernstein, PR; Bhat, T; Bhonde, M; Bommakanti, A; Bora, P; Francis, A; George, KS; Gole, G; Goyal, H; Gundu, J; Gupta, NR; Gupta, R; Hajare, AK; Jadhav, GR; Jagdale, AR; Jana, G; Kale, R; Kamalakannan, P; Kamble, N; Kamboj, RK; Karche, NP; Khanwalkar, H; Khedkar, N; Kukreja, G; Kumar, P; Kumar, R; Kurhade, SP; Limaye, R; Mallurwar, S; Modi, D; Naidu, S; Naik, KR; Narasimham, L; Nemmani, K; Nigade, PB; Pagdala, V; Palle, VP; Patil, V; Pawar, S; Pawar, Y; Phukan, S; Powar, RG; Praveen Kumar, VR; Rao Irlapati, N; Shaikh, JS; Shankar, RB; Sharma, S; Singh, M; Sinha, N; Thube, BR; Tilekar, AR; Volam, H; Wahid, S, 2020
)
0.56
" A high-fat meal slightly increased bioavailability at 600 mg but not at lower doses; this is not considered clinically significant, and rucaparib can be taken with or without food."( Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Beltman, J; Giordano, H; Goble, S; Green, ML; Harding, TC; Ma, SC; Maloney, L; Simmons, AD; Xiao, JJ, 2022
)
1.21
" Rucaparib has moderate oral bioavailability and can be dosed with or without food."( Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Beltman, J; Giordano, H; Harding, TC; Liao, M; Maloney, L; Simmons, AD; Xiao, JJ, 2022
)
1.88

Dosage Studied

This phase I study (CO-338-044; NCT02740712) evaluated the effect of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib on the pharmacokinetics (PK) of caffeine 200mg, warfarin 10mg, omeprazole 40mg, and midazolam 2mg.

ExcerptRelevanceReference
"Poly(ADP-ribose) polymerase-1 (PARP) inhibitors (PARPi) exploit tumour-specific defects in homologous recombination DNA repair and continuous dosing is most efficacious."( Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
Berry, P; Boddy, AV; Curtin, NJ; Hostomsky, Z; Jones, C; Kyle, S; Los, G; Murray, J; Patterson, M; Plummer, ER; Thomas, H, 2014
)
0.71
"Rucaparib accumulates and is retained in tumour cells and inhibits PARP for long periods such that weekly schedules have equivalent anticancer activity to daily dosing in a pre-clinical model, suggesting that clinical evaluation of alternative schedules of rucaparib should be considered."( Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
Berry, P; Boddy, AV; Curtin, NJ; Hostomsky, Z; Jones, C; Kyle, S; Los, G; Murray, J; Patterson, M; Plummer, ER; Thomas, H, 2014
)
2.15
") and subsequently oral rucaparib were assessed, using a range of dosing schedules, to determine the safety, tolerability, dose-limiting toxic effects and pharmacodynamic (PD) and pharmacokinetic (PK) profiles."( Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Acton, G; Backholer, Z; Boddy, A; Curtin, N; Drew, Y; Glasspool, R; Halford, S; Hall, G; Highley, M; Jamieson, D; Jayson, G; Ledermann, J; Mangano, R; Murray, J; Plummer, R; Rea, D; Sludden, J, 2016
)
0.95
" rucaparib (intermittent dosing schedule) resulted in an objective response rate (ORR) of only 2% but with 41% (18 out of 44) patients achieved stable disease for ⩾12 weeks and 3 patients maintaining disease stabilisation for >52 weeks."( Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Acton, G; Backholer, Z; Boddy, A; Curtin, N; Drew, Y; Glasspool, R; Halford, S; Hall, G; Highley, M; Jamieson, D; Jayson, G; Ledermann, J; Mangano, R; Murray, J; Plummer, R; Rea, D; Sludden, J, 2016
)
1.55
" The key lessons learned from this study is that continuous rucaparib dosing is required for optimal response, the recommended phase 2 dose (RP2D) for continuous oral scheduling has not been established and requires further exploration and, thirdly, the use of a PD biomarker to evaluate dose-response has its limitations."( Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Acton, G; Backholer, Z; Boddy, A; Curtin, N; Drew, Y; Glasspool, R; Halford, S; Hall, G; Highley, M; Jamieson, D; Jayson, G; Ledermann, J; Mangano, R; Murray, J; Plummer, R; Rea, D; Sludden, J, 2016
)
0.88
" Simulations were conducted to evaluate different dosing regimens."( PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Curtin, NJ; Kern, KA; Kirkpatrick, TR; Li, C; Plummer, R; Sam, WJ; Shalinsky, DR; Sun, W; Wang, DD; Zhang, S, 2015
)
0.61
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
"Patients were randomized 2:1 to receive either oral rucaparib at a dosage of 600 mg twice daily or placebo."( Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Aghajanian, C; Amenedo Gancedo, M; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI, 2021
)
1.17
"3] years) enrolled and dosed in ARIEL2 and ARIEL3, 22 (2."( Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
Aghajanian, C; Coleman, RL; Colombo, N; Dean, A; Goble, S; Harding, T; Kaufmann, SH; Kwan, TT; Ledermann, JA; Lin, KK; Lorusso, D; Maloney, L; McNeish, IA; Oaknin, A; Oza, AM; Ray-Coquard, I; Severson, E; Swisher, EM; Tinker, AV; Vo, LT; Weberpals, J, 2021
)
0.82
" Patients received nivolumab 480 mg every 4 weeks plus rucaparib 600 mg two times per day (nivolumab dosing ≤2 years)."( Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Amin, NP; Armstrong, AJ; Bastos, DA; Bhagavatheeswaran, P; Burotto, M; Castellano, D; Fizazi, K; Fléchon, A; Goh, JC; Gravis, G; Grimm, MO; Kwan, EM; Lacombe, L; Li, J; Loehr, A; Mahammedi, H; McCune, SL; Pachynski, RK; Perez-Gracia, J; Petrylak, DP; Retz, M; Saad, F; Shaffer, DR; Ünsal-Kaçmaz, K; Vázquez Limón, JC; Wang, X; Zschäbitz, S, 2022
)
1.32
" Steady state was achieved after continuous twice-daily dosing for a week."( Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Beltman, J; Giordano, H; Harding, TC; Liao, M; Maloney, L; Simmons, AD; Xiao, JJ, 2022
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitorAn EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of a NAD(+) ADP-ribosyltransferase (EC 2.4.2.30).
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
azepinoindoleAny organic heterotricyclic compound with a skeleton consisting of an azepine ring fused to an indole.
caprolactamsA lactam in which the amide bond is contained within a seven-membered ring, which includes the amide nitrogen and the carbonyl carbon.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency18.55690.00529.466132.9993AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.77240.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency17.12690.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency6.00810.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency26.83700.00108.379861.1304AID1645840
tyrosine-protein kinase YesHomo sapiens (human)Potency0.30750.00005.018279.2586AID686947
Interferon betaHomo sapiens (human)Potency15.41970.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency6.00810.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Poly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)IC50 (µMol)7.46770.00190.62935.0000AID1064834; AID1428391; AID1895769
Poly [ADP-ribose] polymerase 1Homo sapiens (human)IC50 (µMol)0.06590.00020.81239.8100AID1205269; AID1248040; AID1276413; AID1374585; AID1428384; AID1428385; AID1428386; AID1508887; AID1638255; AID1682011; AID1802336; AID1871234; AID1872299; AID1876450; AID1895766; AID1909228
Poly [ADP-ribose] polymerase 1Homo sapiens (human)Ki0.00140.00060.65955.0000AID1064836; AID1631788; AID1638255; AID1682011; AID1872298
Protein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)IC50 (µMol)32.47972.40006.40979.0000AID1428398
Protein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)IC50 (µMol)8.87131.73785.66258.9125AID1428397
Protein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)IC50 (µMol)1.43330.56234.10539.7724AID1428394; AID1428395
Protein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)IC50 (µMol)6.62850.07902.43076.6500AID1428396
Poly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)IC50 (µMol)0.45230.00210.67505.1300AID1064833; AID1428393
Poly [ADP-ribose] polymerase 2Homo sapiens (human)IC50 (µMol)0.04970.00010.21886.6000AID1428387; AID1428388; AID1508888; AID1682012; AID1871235; AID1872300; AID1876451; AID1895767; AID1909171
Poly [ADP-ribose] polymerase 2Homo sapiens (human)Ki0.00070.00070.00480.0175AID1682012
Protein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)IC50 (µMol)0.83540.33001.68274.3900AID1428390
Protein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)IC50 (µMol)0.45970.00351.12186.3000AID1428389
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Poly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)Kd10.00000.00800.05370.1000AID1895781
Poly [ADP-ribose] polymerase 1Homo sapiens (human)EC50 (µMol)0.01080.00040.18093.0000AID1276416; AID1683865
Poly [ADP-ribose] polymerase 1Homo sapiens (human)Kd0.00320.00020.43565.3100AID1895777
Protein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)Kd3.10003.10006.06009.7000AID1895786
Protein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)Kd3.10003.10003.10003.1000AID1895785
Protein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)Kd10.00001.10001.10001.1000AID1895784
Protein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)Kd2.90001.00001.95002.9000AID1895790
Poly [ADP-ribose] polymerase 2Homo sapiens (human)EC50 (µMol)0.00470.00250.00840.0240AID1276416
Poly [ADP-ribose] polymerase 2Homo sapiens (human)Kd0.02600.00030.29141.4000AID1895778
Protein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)Kd0.50300.00070.20430.5030AID1895780
Protein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)EC50 (µMol)0.00470.00250.00840.0240AID1276416
Protein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)Kd0.26700.00580.24560.7000AID1895779
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (164)

Processvia Protein(s)Taxonomy
peptidyl-serine phosphorylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
peptidyl-threonine phosphorylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein polyubiquitinationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mitotic spindle organizationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein transportPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mRNA transportPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
spindle assemblyPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cell divisionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomerase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein localization to chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomere cappingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of telomeric DNA bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of maintenance of mitotic sister chromatid cohesion, telomericPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
pentose-phosphate shunt, oxidative branchGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
response to nutrient levelsGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
response to alcoholGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
regulation of cortisol biosynthetic processGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
glucose metabolic processGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrion organizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA metabolic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of protein localizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to oxidative stressPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein modification processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
telomere maintenancePoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
double-strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
apoptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to gamma radiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
carbohydrate biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein autoprocessingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
signal transduction involved in regulation of gene expressionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
macrophage differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of DNA-templated transcription, elongationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to insulin stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to UVPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of circadian sleep/wake cycle, non-REM sleepPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
decidualizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of catalytic activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of mitochondrial depolarizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of SMAD protein signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of necroptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein localization to chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to zinc ionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
replication fork reversalPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of cGAS/STING signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of protein localization to nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of single strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to aldosteronePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of adipose tissue developmentPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to amyloid-betaPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of myofibroblast differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of base-excision repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to nerve growth factor stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ATP generation from poly-ADP-D-ribosePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of ATP biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
protein poly-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
negative regulation of gene expressionProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
negative regulation of gene expressionProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
negative regulation of tyrosine phosphorylation of STAT proteinProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
innate immune responseProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
negative regulation of DNA-templated transcriptionProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
positive regulation of interleukin-4-mediated signaling pathwayProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
protein poly-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
chromatin organizationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of gene expressionProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
viral protein processingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
translesion synthesisProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of DNA-templated transcriptionProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of fibroblast proliferationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein poly-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein auto-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of protein K63-linked ubiquitinationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein poly-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
DNA damage checkpoint signalingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
positive regulation of defense response to virus by hostProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
double-strand break repairProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
post-transcriptional regulation of gene expressionProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
negative regulation of gene expressionProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
cell migrationProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
viral protein processingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
positive regulation of chromatin bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
negative regulation of catalytic activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
innate immune responseProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
positive regulation of DNA-templated transcriptionProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
defense response to virusProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
regulation of response to type II interferonProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
positive regulation of type II interferon-mediated signaling pathwayProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
positive regulation of protein localization to nucleusProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
protein auto-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
endoplasmic reticulum unfolded protein responseProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
viral protein processingProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
endoplasmic reticulum unfolded protein responseProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
IRE1-mediated unfolded protein responseProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
protein auto-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
cellular response to leukemia inhibitory factorProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
negative regulation of cytoplasmic translationProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
protein auto-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
protein polyubiquitinationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein localization to chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of telomere cappingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nuclear envelope organizationProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
spermatogenesisProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
protein transportProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
cell differentiationProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
mRNA transportProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
protein auto-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
DNA repairPoly [ADP-ribose] polymerase 2Homo sapiens (human)
base-excision repairPoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA ADP-ribosylationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
decidualizationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
positive regulation of cell growth involved in cardiac muscle cell developmentPoly [ADP-ribose] polymerase 2Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
response to oxygen-glucose deprivationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
extrinsic apoptotic signaling pathwayPoly [ADP-ribose] polymerase 2Homo sapiens (human)
hippocampal neuron apoptotic processPoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA repair-dependent chromatin remodelingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
double-strand break repairPoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA repairProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
inflammatory responseProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
DNA damage responseProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
response to xenobiotic stimulusProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
protein modification processProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
regulation of telomerase activityProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
protein poly-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
telomere maintenanceProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
double-strand break repairProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
positive regulation of DNA ligationProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
regulation of mitotic spindle organizationProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
protein localization to site of double-strand breakProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
DNA ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
negative regulation of isotype switchingProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
protein auto-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
negative regulation of telomerase RNA reverse transcriptase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
double-strand break repairProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (72)

Processvia Protein(s)Taxonomy
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
histone bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
glucose-6-phosphate dehydrogenase activityGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
6-phosphogluconolactonase activityGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
carbohydrate bindingGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
glucose 1-dehydrogenase (NAD+) activityGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
glucose 1-dehydrogenase (NADP+) activityGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
glucose 1-dehydrogenase [NAD(P)] activityGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
NADP bindingGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatin bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
damaged DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein kinase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear estrogen receptor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleosome bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ubiquitin protein ligase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
identical protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein homodimerization activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
histone deacetylase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
R-SMAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator activator activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-tyrosine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-histidine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BS6 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H3S10 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription corepressor activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+ bindingProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
enzyme bindingProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
transcription corepressor activityProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
K63-linked polyubiquitin modification-dependent protein bindingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
DNA-binding transcription factor bindingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
transcription corepressor activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
NAD+ bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
transcription corepressor activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
enzyme inhibitor activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
enzyme bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
histone bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
ubiquitin-like protein ligase bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
ADP-D-ribose bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
STAT family protein bindingProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
NAD+-protein-C-terminal glycine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
NAD+- protein-cysteine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
protein serine/threonine kinase activator activityProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
kinase bindingProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
kinase bindingProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
protein serine/threonine kinase activator activityProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
RNA bindingProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
metal ion bindingProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
NAD+- protein-cysteine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
metal ion bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
NAD+- protein-cysteine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
chromatin bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
damaged DNA bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleosome bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
poly-ADP-D-ribose bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+-protein-serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
poly-ADP-D-ribose modification-dependent protein bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA bindingProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
enzyme bindingProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
catalytic activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
Golgi membranePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
pericentriolar materialPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
Golgi apparatusPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear membranePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mitotic spindle polePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear porePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
endoplasmic reticulum lumenGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
endoplasmic reticulumGDH/6PGL endoplasmic bifunctional proteinHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear replication forkPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
membranePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-containing complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-DNA complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
cytosolProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
plasma membraneProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
membraneProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP14Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
nucleolusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
Golgi apparatusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
cytosolProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
nucleoplasmProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
mitochondrionProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
cytosolProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
membraneProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
site of DNA damageProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
protein-containing complexProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP9Homo sapiens (human)
endoplasmic reticulum tubular networkProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
nuclear envelopeProtein mono-ADP-ribosyltransferase PARP8Homo sapiens (human)
nuclear envelopeProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
endoplasmic reticulumProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
endoplasmic reticulum membraneProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
cytosolProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
membraneProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
endoplasmic reticulum tubular networkProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
nuclear envelopeProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
endoplasmic reticulum tubular networkProtein mono-ADP-ribosyltransferase PARP16Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP12Homo sapiens (human)
Golgi membranePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
pericentriolar materialPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
perinuclear region of cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nuclear envelopeProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
nucleoplasmProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
cytosolProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
nuclear bodyProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
nuclear poreProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP11Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 2Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
nucleoplasmProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
cytosolProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
spindle microtubuleProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
membraneProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
extracellular exosomeProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
ribonucleoprotein complexProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP4Homo sapiens (human)
nucleoplasmProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
centrosomeProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
centrioleProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
nuclear bodyProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
site of double-strand breakProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
intercellular bridgeProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
nucleolusProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
site of double-strand breakProtein mono-ADP-ribosyltransferase PARP3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (149)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1374585Inhibition of recombinant human GST-tagged PARP1 expressed in Escherichia coli using damaged DNA as substrate after 30 mins in presence of NAD+ by resazurin dye based fluorescence assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Design, synthesis and anticancer activities evaluation of novel 5H-dibenzo[b,e]azepine-6,11-dione derivatives containing 1,3,4-oxadiazole units.
AID1064834Inhibition of human 6xhis-tagged ARTD5 (1030 to 1317) expressed in Escherichia coli Rosetta2 (DE3) cells using NAD+ as substrate by fluorescence assay2014ACS medicinal chemistry letters, Jan-09, Volume: 5, Issue:1
Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
AID1895780Binding affinity to PARP4 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1508887Inhibition of PARP1 (unknown origin)
AID1276422Cytotoxicity against human MRC5 cells2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymer
AID1876452Selectivity index, ratio of IC50 for human PARP2 to IC50 for human PARP12022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID492551Toxicity in iv infused human patients assessed as maximum tolerated dose2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
AID1682011Inhibition of N-terminal GST-tagged human full length PARP1 (2 to 1041 residues) expressed in baculovirus infected Sf9 cells using histone mixture (H2A and H2B) and biotinylated NAD+ as substrate in presence of activated DNA incubated for 60 mins by chemi2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
AID1872300Inhibition of PARP2 (unknown origin)2022European journal of medicinal chemistry, Feb-15, Volume: 230Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
AID1895766Inhibition of human recombinant N-terminal 6His-6Lys-TEV tagged PARP1 full length expressed in pFastBac expression system incubated for 4 hrs by fluorescence anisotropy binding assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1895784Binding affinity to PARP8 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1428395Inhibition of recombinant human His6-tagged PARP10 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1638256Protein binding in plasma (unknown origin)2019European journal of medicinal chemistry, Mar-01, Volume: 165Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
AID1428394Inhibition of full length recombinant human His6-tagged PARP10 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1663794Synergistic cytotoxicity against human patient derived GBM cells assessed as reduction in cell viability measured after 48 hrs in presence of temozolomide by Hoechst staining based assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
AID1428384Inhibition of full length recombinant human His6-tagged PARP1 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1876455Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1895791Binding affinity to PARP1 (unknown origin) assessed as residence time2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1428398Inhibition of recombinant human His6-tagged PARP15 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1895789Binding affinity to PARP14 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1428391Inhibition of recombinant human TNKS1 ADP-ribosyltransferase/sterile alpha motif domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1895768Selectivity ratio of IC50 for PARP1 (unknown origin) to IC50 for PARP2 (unknown origin )2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1872298Binding affinity to PARP1 (unknown origin) assessed as inhibition constant2022European journal of medicinal chemistry, Feb-15, Volume: 230Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
AID1276417Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymer
AID1895777Binding affinity to PARP1 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1682077Selectivity index, ratio of IC50 for inhibition of N-terminal GST-tagged human PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 cells to IC50 for inhibition of N-terminal GST-tagged human full length PARP1 (2 to 1041 residues) expressed in 2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
AID1876459In vivo inhibition of PARP1 in athymic BALB/c mouse xenografted with human BRCA1 mutant MDA-MB-436 cells assessed as prevention of PAR formation 50 mg/kg/day, po measured after 48 hrs by Western blot analysis2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1895786Binding affinity to PARP10 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1428387Inhibition of full length recombinant human His6-tagged PARP2 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1428396Inhibition of recombinant human His6-tagged PARP12 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1895769Inhibition of human recombinant PARP5a (E1023 to T1327 amino acids) incubated for 4 hrs by fluorescence anisotropy binding assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1428399Inhibition of full length recombinant human His6-tagged PARP16 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1682012Inhibition of N-terminal GST-tagged human PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 cells using histone mixture (H2A and H2B) and biotinylated NAD+ as substrate in presence of activated DNA incubated for 60 mins by chemiluminescence 2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
AID1638255Inhibition of human recombinant full-length PARP1 after 4 mins by [32P]NAD+ incorporation assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
AID1683865Inhibition of human PARP-1 catalytic domain (662 to 1011 residues) expressed in Escherichia coli BL21(DE3) cells incubated for 0.5 hrs by fluorescence polarization assay based DNA trapping activity assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
AID1428393Inhibition of recombinant human TNKS2 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1663793Cytotoxicity against human patient derived GBM cells assessed as reduction in cell viability measured after 48 hrs by Hoechst staining based assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
AID1663799Synergistic antiproliferative activity against human patient derived GBM cells assessed as reduction in cell proliferation measured after 48 hrs in presence of temozolomide by Edu incorporation assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
AID1248042Anticancer activity against human BRCA1-deficient MDA-MB-436 cells after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
AID492553Half life in iv dosed human patient2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
AID1064833Inhibition of human N-terminal 6xhis-tagged ARTD6 (873 to 1161) expressed in Escherichia coli Rosetta2 (DE3) cells using NAD+ as substrate by fluorescence assay2014ACS medicinal chemistry letters, Jan-09, Volume: 5, Issue:1
Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
AID1276416Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymer
AID1428390Inhibition of recombinant human His6-tagged PARP4 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1276421Cytotoxicity against BRCA1-deficient human MX1 cells2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymer
AID1682063Potentiation of anticancer activity against human SK-ES-1 cells harboring EWSF1 translocation xenografted in SCID/nude mouse assessed as tumor growth inhibition at 3 mg/kg, po bid for 12 days co-administered with TMZ measured up to 9 weeks post drug admin2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
AID1895788Binding affinity to PARP12 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1428385Inhibition of recombinant human His6-tagged PARP1 C-3-zinc finger domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1374584Antiproliferative activity against human OVCAR3 cells after 24 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Design, synthesis and anticancer activities evaluation of novel 5H-dibenzo[b,e]azepine-6,11-dione derivatives containing 1,3,4-oxadiazole units.
AID1428389Inhibition of full length recombinant human His6-tagged PARP3 expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1895782Binding affinity to PARP5b (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1895778Binding affinity to PARP2 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1876449Inhibition of human PARP2 using NAD+ as substrate at 5 nM incubated for 1 hr by ELISA relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1895787Binding affinity to PARP11 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1871235Inhibition of human recombinant PARP2 by ELISA2021European journal of medicinal chemistry, Jan-15, Volume: 210Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer.
AID1205269Inhibition of PARP1 (unknown origin)2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
AID1428386Inhibition of recombinant human His6-tagged PARP1 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1276413Inhibition of human PARP1 using [3H]NAD as substrate after 1 min by microplate scintillation counting analysis2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymer
AID1179154In vivo inhibition of PARP activity in peripheral blood mononuclear cells of advanced solid tumor patient at 12 mg/m2 co-treated with rucaparib and temzolomide2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Development of synthetic lethality anticancer therapeutics.
AID1276419Cytotoxicity against BRCA2-deficient human Capan1 cells2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymer
AID492552Biodistribution in human patient urine2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
AID1663798Antiproliferative activity against human patient derived GBM cells assessed as reduction in cell proliferation measured after 48 hrs by Edu incorporation assay2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
AID1895770Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1909228Inhibition of PARP1 (unknown origin)2022Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
AID1871234Inhibition of human recombinant PARP1 by ELISA2021European journal of medicinal chemistry, Jan-15, Volume: 210Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer.
AID1895790Binding affinity to PARP16 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1895783Binding affinity to PARP7 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1248040Inhibition of PARP1 (unknown origin)2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
AID1682061Potentiation of anticancer activity against human CAPAN-1 cells harboring BRCA mutant xenografted in SCID/nude mouse assessed as tumor growth inhibition at 3 mg/kg, po bid for 12 days co-administered with TMZ measured up to 9 weeks post-drug administratio2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
AID1428388Inhibition of recombinant human His6-tagged PARP2 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1876450Inhibition of human PARP1 using NAD+ as substrate incubated for 1 hr by ELISA2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1909171Inhibition of PARP2 (unknown origin)2022Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
AID1876453Antiproliferative activity against human BRCA mutant MX1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1682058Potentiation of anticancer activity against human MDA-MB-436 cells harboring BRCA mutant xenografted in SCID/nude mouse assessed as tumor growth inhibition at 3 mg/kg, po bid for 12 days co-administered with TMZ measured up to 9 weeks post-drug administra2020Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24
Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.
AID1428397Inhibition of recombinant human His6-tagged PARP14 ADP-ribosyltransferase domain expressed in Escherichia coli BL21(DE3) preincubated for 15 mins followed by biotinylated NAD+ addition by chemiluminescence assay2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
AID1508888Inhibition of PARP2 (unknown origin)
AID1895767Inhibition of human recombinant N-terminal Avi-6His-TEV tagged PARP2 full length expressed in pFastBac expression system incubated for 4 hrs by fluorescence anisotropy binding assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1876454Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1895779Binding affinity to PARP3 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1895781Binding affinity to PARP5a (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1631788Inhibition of PARP1 (unknown origin)2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.
AID1895785Binding affinity to PARP9 (unknown origin) assessed as apparent dissociation constant2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
AID1248041Anticancer activity against human MCF7 cells after 96 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
AID1876448Inhibition of human PARP1 using NAD+ as substrate at 5 nM incubated for 1 hr by ELISA relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1064836Inhibition of human full-length recombinant ARTD1 assessed as incorporation of [32P]NAD+ by scintillation counting analysis2014ACS medicinal chemistry letters, Jan-09, Volume: 5, Issue:1
Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
AID1872301Selectivity ratio of IC50 for PARP2 (unknown origin) to IC50 for PARP1 (unknown origin)2022European journal of medicinal chemistry, Feb-15, Volume: 230Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
AID1876451Inhibition of human PARP2 using NAD+ as substrate incubated for 1 hr by ELISA2022European journal of medicinal chemistry, Jan-05, Volume: 227Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2.
AID1872299Inhibition of PARP1 (unknown origin)2022European journal of medicinal chemistry, Feb-15, Volume: 230Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
AID1880786Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
Fluorescent PARP Inhibitors Applied To Intracranial Glioblastoma: Accumulation and Persistence In Vivo.
AID1880783Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay2022ACS medicinal chemistry letters, Jun-09, Volume: 13, Issue:6
Fluorescent PARP Inhibitors Applied To Intracranial Glioblastoma: Accumulation and Persistence In Vivo.
AID1663804Antiproliferative activity against human patient derived GBM cells assessed as reduction in cell proliferation measured after 48 hrs by Edu incorporation assay relative to compound alone2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
AID493040Navigating the Kinome2011Nature chemical biology, Apr, Volume: 7, Issue:4
Navigating the kinome.
AID1346183Human poly(ADP-ribose) polymerase 1 (2.4.2.30 poly(ADP-ribose)polymerases)2007Molecular cancer therapeutics, Mar, Volume: 6, Issue:3
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
AID1802336In Vitro PARP1 Activity Assay from Article 10.1016/j.chembiol.2016.10.011: \\Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.\\2016Cell chemical biology, Dec-22, Volume: 23, Issue:12
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.
AID1802337H6PD Activity Assay from Article 10.1016/j.chembiol.2016.10.011: \\Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.\\2016Cell chemical biology, Dec-22, Volume: 23, Issue:12
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (231)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (2.16)29.6817
2010's119 (51.52)24.3611
2020's107 (46.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.83 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index6.12 (4.65)
Search Engine Demand Index101.01 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (61.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials36 (15.25%)5.53%
Reviews41 (17.37%)6.00%
Case Studies3 (1.27%)4.05%
Observational2 (0.85%)0.25%
Other154 (65.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (64)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
"A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating BRCAness Genotype (ROAR)" [NCT03533946]Phase 27 participants (Actual)Interventional2019-05-20Active, not recruiting
A Randomized Double-blind Placebo-controlled Phase II Trial of Rucaparib Maintenance Therapy for Patients With Locally Advanced Cervical Cancer. [NCT03795272]Phase 20 participants (Actual)Interventional2019-10-01Withdrawn(stopped due to Lack of financial support)
A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors [NCT04276376]Phase 21,000 participants (Anticipated)Interventional2019-04-12Suspended(stopped due to The manufacturer (Clovis) supplying Rucaparib has gone bankrupt and is no longer able to fund the trial and supply the product.)
A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer [NCT04253262]Phase 1/Phase 213 participants (Actual)Interventional2020-04-03Active, not recruiting
Arterial Hypertension With PARP Inhibitors in Cancer Patients: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database (ArteRIB) [NCT04774406]2,336 participants (Actual)Observational2021-02-24Completed
A Phase 2, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation [NCT03140670]Phase 246 participants (Actual)Interventional2017-09-05Terminated(stopped due to Loss of funding)
A Randomized, Molecular Driven Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, Selected According to HRD Status, in Patients With Advanced (Stage III B-C-IV) Ovarian [NCT03462212]Phase 1/Phase 2290 participants (Anticipated)Interventional2021-03-17Recruiting
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile [NCT02925234]Phase 21,550 participants (Anticipated)Interventional2016-08-31Recruiting
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients [NCT04227522]Phase 3190 participants (Anticipated)Interventional2020-06-08Active, not recruiting
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer [NCT03840200]Phase 151 participants (Actual)Interventional2019-06-12Completed
A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients With Triple Negative Breast Cancer With an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy [NCT03542175]Phase 131 participants (Actual)Interventional2018-05-23Active, not recruiting
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME) [NCT03995017]Phase 1/Phase 234 participants (Actual)Interventional2020-01-09Active, not recruiting
A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium [NCT03476798]Phase 249 participants (Actual)Interventional2018-06-29Completed
Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer [NCT03552471]Phase 125 participants (Actual)Interventional2018-07-12Active, not recruiting
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers [NCT04209595]Phase 1/Phase 210 participants (Actual)Interventional2020-04-08Active, not recruiting
Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors in Response to the PARP Inhibitor Rucaparib [NCT03911453]Early Phase 120 participants (Actual)Interventional2019-04-19Active, not recruiting
Phase II Study of Combination Rucaparib With Nivolumab in Platinum-Sensitive Small Cell Lung Carcinoma Patients as Maintenance After Induction Therapy With Platinum Doublet [NCT03958045]Phase 233 participants (Actual)Interventional2019-09-04Active, not recruiting
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) [NCT03768063]Phase 31,000 participants (Anticipated)Interventional2019-02-28Recruiting
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer [NCT02873962]Phase 273 participants (Actual)Interventional2016-11-10Active, not recruiting
A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer [NCT00664781]Phase 278 participants (Actual)Interventional2007-12-31Completed
Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma [NCT04624178]Phase 220 participants (Actual)Interventional2020-11-05Active, not recruiting
A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer [NCT03101280]Phase 129 participants (Actual)Interventional2017-04-27Completed
A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes [NCT04171700]Phase 283 participants (Actual)Interventional2020-01-16Terminated(stopped due to The study was terminated due to a change in development priorities.)
Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma [NCT03654833]Phase 2186 participants (Actual)Interventional2019-01-28Active, not recruiting
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146 [NCT01074970]Phase 2135 participants (Actual)Interventional2010-02-28Completed
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 ) [NCT01968213]Phase 3564 participants (Actual)Interventional2014-04-07Completed
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency [NCT03442556]Phase 218 participants (Actual)Interventional2018-08-24Active, not recruiting
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma [NCT03397394]Phase 297 participants (Actual)Interventional2018-06-01Terminated(stopped due to Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment.)
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency [NCT02952534]Phase 2277 participants (Actual)Interventional2017-02-15Completed
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB [NCT03337087]Phase 1/Phase 218 participants (Anticipated)Interventional2018-11-02Active, not recruiting
A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer [NCT03572478]Phase 1/Phase 212 participants (Actual)Interventional2018-08-14Terminated(stopped due to The study was terminated due to lack of efficacy.)
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer [NCT04455750]Phase 361 participants (Actual)Interventional2021-02-19Active, not recruiting
A Phase 2, Multi-Stage, Multi-Center Trial Exploring The Safety And Efficacy Of AG-014699 In Subjects With Diffuse Diabetic Macular Edema (DME) Involving The Center Of The Retina [NCT00457470]Phase 20 participants (Actual)Interventional2007-06-30Withdrawn(stopped due to Cancelled before first patient enrolled)
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [NCT02855944]Phase 3349 participants (Actual)Interventional2017-03-01Completed
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer [NCT03338790]Phase 2292 participants (Actual)Interventional2017-12-19Active, not recruiting
CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib [NCT04676334]Phase 334 participants (Actual)Interventional2021-03-22Completed
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma [NCT03694262]Phase 230 participants (Actual)Interventional2019-07-19Completed
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy [NCT03639935]Phase 232 participants (Actual)Interventional2019-03-28Active, not recruiting
A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function [NCT03521037]Phase 116 participants (Actual)Interventional2018-02-27Completed
A Phase 1, Open-label, Safety and Pharmacokinetic Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor [NCT03499444]Phase 129 participants (Actual)Interventional2018-02-06Completed
An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors [NCT02986100]Phase 16 participants (Actual)Interventional2016-11-30Completed
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer) [NCT02935634]Phase 2190 participants (Actual)Interventional2016-11-29Completed
A Phase 1, Open-label, Multiple-probe Drug-drug Interaction Study to Determine the Effect of Rucaparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, and Digoxin in Patients With Advanced Solid Tumors [NCT02740712]Phase 117 participants (Actual)Interventional2016-04-30Completed
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor [NCT01482715]Phase 1/Phase 2136 participants (Actual)Interventional2011-11-30Completed
A Phase 1, Open-label, Drug-drug-interaction Study to Determine the Effect of Rucaparib on the Pharmacokinetics of Oral Rosuvastatin (Arm A) and Oral Contraceptives (Ethinylestradiol and Levonorgestrel) (Arm B) in Patients With Advanced Solid Tumors [NCT03954366]Phase 136 participants (Actual)Interventional2019-04-25Completed
Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial [NCT02678182]Phase 2924 participants (Anticipated)Interventional2015-02-28Recruiting
Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) [NCT03413995]Phase 230 participants (Anticipated)Interventional2018-09-10Recruiting
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) [NCT03522246]Phase 31,000 participants (Anticipated)Interventional2018-05-14Active, not recruiting
Pancytopenia Related to PARP Inhibitors in Cancer Patients : an Observational and Retrospective Study Using the WHO's Pharmacovigilance Database (PancytoRIB) [NCT04774627]200 participants (Actual)Observational2021-02-07Completed
A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature [NCT02505048]Phase 241 participants (Actual)Interventional2016-03-31Completed
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab [NCT03559049]Phase 1/Phase 225 participants (Actual)Interventional2018-12-24Active, not recruiting
A Phase 1b, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer [NCT04179396]Phase 18 participants (Actual)Interventional2019-12-05Completed
An Open-label, Multicentric, Phase Ib/II Study to Assess the Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Nira [NCT04826198]Phase 1/Phase 226 participants (Anticipated)Interventional2020-10-05Recruiting
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies [NCT02711137]Phase 1/Phase 2137 participants (Actual)Interventional2016-05-18Terminated(stopped due to Study terminated due to safety issues.)
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency [NCT02975934]Phase 3405 participants (Actual)Interventional2017-06-13Active, not recruiting
A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) [NCT03824704]Phase 21 participants (Actual)Interventional2019-08-23Terminated(stopped due to Sponsor made a business decision to discontinue the study due to low accrual.)
A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) [NCT01891344]Phase 2491 participants (Actual)Interventional2013-10-30Completed
A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer [NCT03617679]Phase 2138 participants (Anticipated)Interventional2019-03-06Active, not recruiting
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study) [NCT03845296]Phase 264 participants (Actual)Interventional2019-04-16Active, not recruiting
SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor [NCT03992131]Phase 1/Phase 225 participants (Actual)Interventional2019-06-28Terminated(stopped due to Due to a change in development priorities, no further clinical development of the lucitanib plus rucaparib or lucitanib plus sacituzumab govitecan combinations is planned at this time.)
A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid [NCT01009190]Phase 185 participants (Actual)Interventional2010-02-28Completed
A Phase 2, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation [NCT02042378]Phase 219 participants (Actual)Interventional2014-04-30Completed
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study [NCT04539327]52 participants (Actual)Observational2020-07-29Completed
Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair [NCT03318445]Phase 122 participants (Actual)Interventional2018-01-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01482715 (12) [back to overview]Food Effect on PK of Rucaparib - Tmax (Part 1 and Part 3)
NCT01482715 (12) [back to overview]Food Effect on PK of Rucaparib - Cmax (Part 1 and Part 3)
NCT01482715 (12) [back to overview]Progression-free Survival (PFS) According to RECIST v1.1, as Assessed by the Investigator (Part 2)
NCT01482715 (12) [back to overview]Overall Survival (Part 2B)
NCT01482715 (12) [back to overview]Overall Response Rate Per RECIST Version 1.1 (Part 2)
NCT01482715 (12) [back to overview]Number of Participants With a Dose Limiting Toxicity (DLT)
NCT01482715 (12) [back to overview]QTcF Value Change From Baseline (Part 1)
NCT01482715 (12) [back to overview]PK Profile of Rucaparib - Tmax (Part 1)
NCT01482715 (12) [back to overview]PK Profile of Rucaparib - Cmax (Part 1)
NCT01482715 (12) [back to overview]PK Profile of Rucaparib - AUC Last (Part 1)
NCT01482715 (12) [back to overview]Duration of Response Per RECIST Version 1.1 (Part 2)
NCT01482715 (12) [back to overview]Food Effect on PK of Rucaparib - AUC Last (Part 1 and Part 3)
NCT01891344 (8) [back to overview]Steady State Trough (Cmin) Level Rucaparib Concentrations
NCT01891344 (8) [back to overview]Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study)
NCT01891344 (8) [back to overview]Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD (Homologous Recombination Deficiency) Subgroups (Part 1 of Study)
NCT01891344 (8) [back to overview]Overall Survival (Part 2 of Study)
NCT01891344 (8) [back to overview]Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study)
NCT01891344 (8) [back to overview]Objective Response Rate (ORR) by RECIST v1.1 and GCIG CA-125 Criteria
NCT01891344 (8) [back to overview]Objective Response Rate (ORR) by RECIST v1.1 (Part 1 of Study)
NCT01891344 (8) [back to overview]Duration of Response Per RECIST v1.1
NCT01968213 (6) [back to overview]Disease Progression According to RECIST v1.1, as Assessed by Independent Radiology Review (IRR), or Death From Any Cause (irrPFS)
NCT01968213 (6) [back to overview]Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS)
NCT01968213 (6) [back to overview]Overall Survival (OS)
NCT01968213 (6) [back to overview]Time to a 4-point Decrease in the Disease-related Symptoms - Physical (DRS-P) Subscale of the FOSI-18
NCT01968213 (6) [back to overview]Time to an 8-point Decrease in the Total Score of the FOSI-18
NCT01968213 (6) [back to overview]Individual Model Parameter Estimates of Rucaparib and Covariates Identification
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]Cmax: Maximum Observed Plasma Concentration of INCB057643.
NCT02711137 (17) [back to overview]Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643
NCT02711137 (17) [back to overview]Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.
NCT02711137 (17) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAE's).
NCT02711137 (17) [back to overview]AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643
NCT02711137 (17) [back to overview]AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
NCT02711137 (17) [back to overview]AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
NCT02711137 (17) [back to overview]Tmax: Time to Maximum Plasma Concentration of INCB057643
NCT02711137 (17) [back to overview]Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02711137 (17) [back to overview]Objective Response Rate (ORR) With INCB057643 in Solid Tumors
NCT02855944 (12) [back to overview]Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 and/or CA-125 Response (Efficacy Population)
NCT02855944 (12) [back to overview]Investigator Assessed Duration of Response (DOR) by RECIST v1.1 (Efficacy Population)
NCT02855944 (12) [back to overview]Investigator Assessed Duration of Response (DOR) by RECIST v1.1 (ITT Population)
NCT02855944 (12) [back to overview]Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 (Efficacy Population)
NCT02855944 (12) [back to overview]Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 (ITT Population)
NCT02855944 (12) [back to overview]Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 and/or CA-125 Response (ITT Population)
NCT02855944 (12) [back to overview]Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population)
NCT02855944 (12) [back to overview]Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population)
NCT02855944 (12) [back to overview]Least Squares Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for the First 6 Cycles (Efficacy Population)
NCT02855944 (12) [back to overview]Least Squares Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for the First 6 Cycles (ITT Population)
NCT02855944 (12) [back to overview]Overall Survival (Efficacy Population)
NCT02855944 (12) [back to overview]Overall Survival (ITT Population)
NCT02935634 (6) [back to overview]Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
NCT02935634 (6) [back to overview]Number of Participants With Laboratory Abnormalities in Specific Liver Tests
NCT02935634 (6) [back to overview]Number of Participants With AEs, SAEs, AEs Leading to Discontinuation, and Death
NCT02935634 (6) [back to overview]Objective Response Rate (ORR) by Investigator
NCT02935634 (6) [back to overview]Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks
NCT02935634 (6) [back to overview]Median Duration of Response (DOR)
NCT02952534 (13) [back to overview]Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR)
NCT02952534 (13) [back to overview]Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Investigator (INV)
NCT02952534 (13) [back to overview]Confirmed PSA Response (≥ 50% Decrease) by Gene as Assessed by Local Laboratory
NCT02952534 (13) [back to overview]Confirmed PSA Response (≥ 90% Decrease) by Gene as Assessed by Local Laboratory
NCT02952534 (13) [back to overview]Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Central Independent Radiology Review (IRR)
NCT02952534 (13) [back to overview]Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Investigator
NCT02952534 (13) [back to overview]Overall Survival (OS) by Gene
NCT02952534 (13) [back to overview]Radiologic Progression-free Survival (rPFS) by Gene in All Patients Per Central Independent Radiology Review (IRR)
NCT02952534 (13) [back to overview]Radiologic Progression-free Survival (rPFS) by Gene in All Patients Per Investigator
NCT02952534 (13) [back to overview]Clinical Benefit Rate (CBR) by Gene Per Central Independent Radiology Review (IRR)
NCT02952534 (13) [back to overview]Clinical Benefit Rate (CBR) by Gene Per Investigator
NCT02952534 (13) [back to overview]Steady State Trough (Cmin) Level Rucaparib Concentrations
NCT02952534 (13) [back to overview]Time to PSA Progression by Gene
NCT02975934 (18) [back to overview]Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA Alteration
NCT02975934 (18) [back to overview]Change in Patient-reported Outcome (PRO) in Participants With a BRCA Alteration: EQ-5D-5L
NCT02975934 (18) [back to overview]Change in Patient-reported Outcome (PRO) in Participants With a BRCA Alteration: FACT-P
NCT02975934 (18) [back to overview]Clinical Benefit Rate (CBR) by IRR at 6 Months in Participants With a BRCA Alteration
NCT02975934 (18) [back to overview]Clinical Benefit Rate (CBR) by IRR at 6 Months in Participants With a BRCA or ATM Alteration Combined
NCT02975934 (18) [back to overview]Duration of Response (DOR) by IRR in Participants With a BRCA Alteration
NCT02975934 (18) [back to overview]Duration of Response (DOR) by IRR in Participants With a BRCA or ATM Alteration Combined
NCT02975934 (18) [back to overview]Interim Overall Survival in Participants With a BRCA Alteration
NCT02975934 (18) [back to overview]Interim Overall Survival in Participants With a BRCA or ATM Alteration Combined
NCT02975934 (18) [back to overview]Objective Response Rate (ORR) by IRR in Participants With a BRCA Alteration
NCT02975934 (18) [back to overview]Objective Response Rate (ORR) by IRR in Participants With a BRCA or ATM Alteration Combined
NCT02975934 (18) [back to overview]PSA Response in Participants With a BRCA Alteration
NCT02975934 (18) [back to overview]PSA Response in Participants With a BRCA or ATM Alteration Combined
NCT02975934 (18) [back to overview]Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA or ATM Alteration Combined
NCT02975934 (18) [back to overview]Time to Prostate Specific Antigen (PSA) Progression in Participants With a BRCA Alteration
NCT02975934 (18) [back to overview]Time to Prostate Specific Antigen (PSA) Progression in Participants With a BRCA or ATM Alteration Combined
NCT02975934 (18) [back to overview]Trough Plasma PK (Cmin) of Rucaparib Based on Sparse Sampling
NCT02975934 (18) [back to overview]Change in Patient-reported Outcome (PRO) in Participants With a BRCA Alteration: BPI-SF
NCT03140670 (6) [back to overview]Duration of Response (DOR)
NCT03140670 (6) [back to overview]Overall Response Rate (ORR)
NCT03140670 (6) [back to overview]Progression-Free Survival (PFS) at 6 Months (PFS6)
NCT03140670 (6) [back to overview]Toxicity at Least Possibly Related to Rucaparib
NCT03140670 (6) [back to overview]Overall Survival
NCT03140670 (6) [back to overview]Disease Control Rate (DCR)
NCT03338790 (9) [back to overview]Number of Participants With Laboratory Abnormalities in Specific Liver Tests
NCT03338790 (9) [back to overview]Number of Deaths
NCT03338790 (9) [back to overview]Number of Participants With Laboratory Values Change From Baseline
NCT03338790 (9) [back to overview]Number of Participants With Adverse Events (AEs)
NCT03338790 (9) [back to overview]Prostate-Specific Antigen Response Rate (RR-PSA)
NCT03338790 (9) [back to overview]Objective Response Rate Per Prostate Cancer Clinical Trials Working Group 3 (ORR-PCWG3)
NCT03338790 (9) [back to overview]Number of Participants With Laboratory Values Change From Baseline
NCT03338790 (9) [back to overview]Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
NCT03338790 (9) [back to overview]Number of Participants With Laboratory Values Change From Baseline
NCT03397394 (4) [back to overview]Progression-free Survival (PFS) According to RECIST v1.1, as Assessed by the Investigator
NCT03397394 (4) [back to overview]Pharmacokinetics - Trough (Cmin) Level Rucaparib Concentrations
NCT03397394 (4) [back to overview]Objective Response Rate (ORR) Per RECIST Version 1.1
NCT03397394 (4) [back to overview]Overall Survival
NCT03476798 (5) [back to overview]Median Overall Survival
NCT03476798 (5) [back to overview]Proportion of Patients Who Had Objective Tumor Response
NCT03476798 (5) [back to overview]Number of Patients Who Experience Toxicity
NCT03476798 (5) [back to overview]Median Progression-free Survival Time
NCT03476798 (5) [back to overview]Proportion of Patients Who Are Progression-free at 6 Months
NCT03572478 (1) [back to overview]Percentage of Participants With Dose Limiting Toxicities (DLT) (Phase 1)
NCT03840200 (12) [back to overview]Percentage of Participants With Adverse Events
NCT03840200 (12) [back to overview]Plasma Concentration of Rucaparib
NCT03840200 (12) [back to overview]Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1)
NCT03840200 (12) [back to overview]Percentage of Participants With Prostate-Specific Antigen Response (PSAR)
NCT03840200 (12) [back to overview]Radiographic Progression Free Survival (rPFS), as Assessed by Prostate Cancer Working Group 3 Criteria (PCWG3)
NCT03840200 (12) [back to overview]Plasma Concentration of Ipatasertib
NCT03840200 (12) [back to overview]Plasma Concentration of Ipatasertib
NCT03840200 (12) [back to overview]Plasma Concentration of Ipatasertib's Metabolite (G-037720)
NCT03840200 (12) [back to overview]Plasma Concentration of Ipatasertib's Metabolite (G-037720)
NCT03840200 (12) [back to overview]Overall Survival (OS) in All Participants
NCT03840200 (12) [back to overview]Duration of Objective Response in Participants With Measurable Disease at Baseline, as Assessed by Investigator Based on RECIST v1.1
NCT03840200 (12) [back to overview]Dose Escalation: Percentage of Participants With Dose-Limiting Toxicities (DLTs) That Determine the Maximum-Tolerated Dose (MTD) of the Ipatasertib and Rucaparib Combination
NCT03845296 (5) [back to overview]Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT03845296 (5) [back to overview]Duration of Response (DoR)
NCT03845296 (5) [back to overview]Investigator-Assessed Progression-Free Survival (IA-PFS)
NCT03845296 (5) [back to overview]Overall Response Rate
NCT03845296 (5) [back to overview]Overall Survival (OS)
NCT03958045 (7) [back to overview]Disease Control Rate
NCT03958045 (7) [back to overview]Quality of Life Scale Baseline
NCT03958045 (7) [back to overview]Quality of Life Scale at Disease Progression
NCT03958045 (7) [back to overview]Quality of Life Scale 4 Months
NCT03958045 (7) [back to overview]Objective Response Rate
NCT03958045 (7) [back to overview]Progression Free Survival
NCT03958045 (7) [back to overview]Overall Survival
NCT04171700 (6) [back to overview]Best Overall Response Rate by Investigator
NCT04171700 (6) [back to overview]Duration of Response
NCT04171700 (6) [back to overview]Progression-free Survival
NCT04171700 (6) [back to overview]Number of Participants Experiencing Treatment-emergent Adverse Events
NCT04171700 (6) [back to overview]Disease Control Rate
NCT04171700 (6) [back to overview]Overall Survival
NCT04179396 (2) [back to overview]Evaluate the PK of Rucaparib in Combination With Other Anticancer Agents for mCRPC.
NCT04179396 (2) [back to overview]Incidence of Dose-Limiting Toxicities (DLTs) in Participants Taking Rucaparib in Combination With Other Anticancer Agents for mCRPC

Food Effect on PK of Rucaparib - Tmax (Part 1 and Part 3)

Tmax = time to maximum concentration following administration of rucaparib. The effect of food on rucaparib PK parameters was assessed over a 24-hour period in blood samples from a subset of patients. Patients were given a single dose of 40 mg or 300 mg rucaparib (Part 1), or 600 mg rucaparib (Part 3) and were randomized to one of two sequences where they were either Fed (with a high-fat meal) or Fasted (without a high-fat meal) on Day -7 or Cycle 1 Day 1. On each day, patients underwent blood sampling for PK at the specified time points. The median Fed and Fasted Tmax values were calculated for each arm. (NCT01482715)
Timeframe: Day -7 to Cycle 1 Day 1, or approximately 7 days

,,
Interventionhr (Median)
Tmax FastedTmax Fed
Rucaparib 300 mg QD4.095.95
Rucaparib 40 mg QD42.55
Rucaparib 600 mg BID4.027.83

[back to top]

Food Effect on PK of Rucaparib - Cmax (Part 1 and Part 3)

Cmax = maximum concentration following administration of rucaparib. The effect of food on rucaparib PK parameters was assessed over a 24-hour period in blood samples from a subset of patients. Patients were given a single dose of 40 mg or 300 mg rucaparib (Part 1), or 600 mg rucaparib (Part 3) and were randomized to one of two sequences where they were either Fed (with a high-fat meal) or Fasted (without a high-fat meal) on Day -7 or Cycle 1 Day 1. On each day, patients underwent blood sampling for PK at the specified time points. The median Fed and Fasted Cmax values were calculated for each arm. (NCT01482715)
Timeframe: Day -7 to Cycle 1 Day 1, or approximately 7 days

,,
Interventionng/mL (Median)
Cmax FastedCmax Fed
Rucaparib 300 mg QD424393
Rucaparib 40 mg QD57.671.1
Rucaparib 600 mg BID585746

[back to top]

Progression-free Survival (PFS) According to RECIST v1.1, as Assessed by the Investigator (Part 2)

PFS is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST, as determined by the investigator or death due to any cause, whichever occurs first. (NCT01482715)
Timeframe: Cycle 1 Day 1 to End of Treatment, up to approximately 51 months

InterventionDays (Median)
Rucaparib 600 mg BID (Part 2A)260
Rucaparib 600 mg BID (Part 2B)280

[back to top]

Overall Survival (Part 2B)

Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death, due to any cause. Patients without a documented event of death will be censored on the date of their last visit. (NCT01482715)
Timeframe: Cycle 1 Day 1 to date of death, assessed up to 38 months

InterventionDays (Median)
Rucaparib 600 mg BID (Part 2B)764

[back to top]

Overall Response Rate Per RECIST Version 1.1 (Part 2)

The confirmed response rate by RECIST v1.1 is defined as the proportion of patients with a confirmed Complete Response (CR) or Partial Response (PR) on subsequent tumor assessment at least 28 days after first response documentation. (NCT01482715)
Timeframe: Time from first dose to date of progression, up to approximately 8 months

InterventionParticipants (Count of Participants)
Rucaparib 600 mg BID (Part 2A)25
Rucaparib 600 mg BID (Part 2B)7

[back to top]

Number of Participants With a Dose Limiting Toxicity (DLT)

The number of Part 1 (Phase 1) patients who experienced dose limiting toxicities after one cycle (21 days) of study drug. (NCT01482715)
Timeframe: Cycle 1 Day 1 to Cycle 1 Day 21

InterventionParticipants (Count of Participants)
Rucaparib 40 mg QD (Part 1)0
Rucaparib 80 mg QD (Part 1)0
Rucaparib 160 mg QD (Part 1)0
Rucaparib 300 mg QD (Part 1)0
Rucaparib 500 mg QD (Part 1)0
Rucaparib 240 mg BID (Part 1)0
Rucaparib 360 mg BID (Part 1)1
Rucaparib 480 mg BID (Part 1)0
Rucaparib 600 mg BID (Part 1)0
Rucaparib 840 mg BID (Part 1)0

[back to top]

QTcF Value Change From Baseline (Part 1)

QTcF value change from baseline by daily dose corrected using Fridericia's method (QTcF). To evaluate the effects of rucaparib on the QT (interval from Q wave to T wave)/QTc (interval corrected for heart rate) interval, all patients underwent serial ECG monitoring at Screening, on Cycle 1 Day -1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 1 Day 22, on Day 1 of all subsequent cycles, at the EOT Visit, and as clinically indicated. Worst post-baseline QTcF value was used to categorize each patient. (NCT01482715)
Timeframe: Screening to End of Treatment, up to approximately 15 months

,,,,,,,,,
InterventionParticipants (Count of Participants)
QTcF Change from Baseline <30 msecQTcF Change from Baseline ≥30 to <60 msecQTcF Change from Baseline ≥60 msec
Rucaparib 160 mg QD400
Rucaparib 240 mg BID300
Rucaparib 300 mg QD900
Rucaparib 360 mg BID800
Rucaparib 40 mg QD500
Rucaparib 480 mg BID900
Rucaparib 500 mg QD310
Rucaparib 600 mg BID700
Rucaparib 80 mg QD300
Rucaparib 840 mg BID300

[back to top]

PK Profile of Rucaparib - Tmax (Part 1)

Tmax = time to maximum concentration following administration of rucaparib (NCT01482715)
Timeframe: Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days

,,,,,,,,,
Interventionhr (Median)
Day 1 TmaxDay 15 Tmax
Rucaparib 160 mg QD43.75
Rucaparib 240 mg BID61.5
Rucaparib 300 mg QD2.52.53
Rucaparib 360 mg BID3.233.3
Rucaparib 40 mg QD2.54
Rucaparib 480 mg BID2.51.51
Rucaparib 500 mg QD44
Rucaparib 600 mg BID44
Rucaparib 80 mg QD1.52.5
Rucaparib 840 mg BID44.04

[back to top]

PK Profile of Rucaparib - Cmax (Part 1)

Cmax = maximum concentration following administration of rucaparib (NCT01482715)
Timeframe: Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days

,,,,,,,,,
Interventionng/mL (Median)
Day 1 CmaxDay 15 Cmax
Rucaparib 160 mg QD255267
Rucaparib 240 mg BID132783
Rucaparib 300 mg QD700439
Rucaparib 360 mg BID6031220
Rucaparib 40 mg QD120159
Rucaparib 480 mg BID10902480
Rucaparib 500 mg QD6991250
Rucaparib 600 mg BID9722330
Rucaparib 80 mg QD119180
Rucaparib 840 mg BID9543030

[back to top]

PK Profile of Rucaparib - AUC Last (Part 1)

AUC last = Area under the plasma concentration-time curve from time 0 to the last recorded observation (NCT01482715)
Timeframe: Cycle 1 Day 1 to Cycle 1 Day 15, or approximately 15 days

,,,,,,,,,
Interventionhr*ng/mL (Median)
Day 1 AUC lastDay 15 AUC last
Rucaparib 160 mg QD27303510
Rucaparib 240 mg BID8756340
Rucaparib 300 mg QD58206090
Rucaparib 360 mg BID41609110
Rucaparib 40 mg QD9152270
Rucaparib 480 mg BID619019400
Rucaparib 500 mg QD767016500
Rucaparib 600 mg BID670019700
Rucaparib 80 mg QD9161870
Rucaparib 840 mg BID593024900

[back to top]

Duration of Response Per RECIST Version 1.1 (Part 2)

Duration of response (DOR) for any confirmed RECIST CR or PR measured from the date of the first occurrence of a response until the first occurrence of PD per RECIST. For patients who continued treatment post-progression, the first date of progression was used for the analysis. Any patients with an ongoing response were censored at the date of the last post-baseline scan. (NCT01482715)
Timeframe: Cycle 1 Day 1 to End of Treatment, up to approximately 48 months

InterventionDays (Median)
Rucaparib 600 mg BID (Part 2A)270
Rucaparib 600 mg BID (Part 2B)318

[back to top]

Food Effect on PK of Rucaparib - AUC Last (Part 1 and Part 3)

AUC last = Area under the plasma concentration-time curve from time 0 to the last recorded observation. The effect of food on rucaparib PK parameters was assessed over a 24-hour period in blood samples from a subset of patients. Patients were given a single dose of 40 mg or 300 mg rucaparib (Part 1), or 600 mg rucaparib (Part 3) and were randomized to one of two sequences where they were either Fed (with a high-fat meal) or Fasted (without a high-fat meal) on Day -7 or Cycle 1 Day 1. On each day, patients underwent blood sampling for PK at the specified time points. The median Fed and Fasted AUC last values were calculated for each arm. (NCT01482715)
Timeframe: Day -7 to Cycle 1 Day 1, or approximately 7 days

,,
Interventionhr*ng/mL (Median)
AUC last FastedAUC last Fed
Rucaparib 300 mg QD54106000
Rucaparib 40 mg QD468794
Rucaparib 600 mg BID705010900

[back to top]

Steady State Trough (Cmin) Level Rucaparib Concentrations

Per protocol, the secondary PK endpoint, trough (Cmin) concentrations of rucaparib were summarized with descriptive statistics overall and by cycle in all patients with at least one PK sample collected. Blood samples for trough level PK analysis of rucaparib were drawn at the following timepoints only: on Day 15 of Cycle 1 and on Day 1 of Cycles 2, 3, and 4. Data for other timepoints is not available. (NCT01891344)
Timeframe: Cycle 1 Day 15 to Cycle 4 Day 1, or approximately 10 weeks

,
Interventionng/mL (Mean)
Cycle 1 Day 15Cycle 2 Day 1Cycle 3 Day 1Cycle 4 Day 1
Part 1 Overall2020.761652.271557.321530.41
Part 2 Overall2276.371689.831552.091629.14

[back to top]

Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study)

Progression-Free Survival (PFS) is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST, as determined by the investigator or death due to any cause, whichever occurs first. Progression is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions. (NCT01891344)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.

InterventionDays (Median)
Part 2: tBRCA223
Part 2: Non-tBRCA LOH+57
Part 2: Non-tBRCA LOH-113
Part 2: Non-tBRCA LOH Unknown110

[back to top]

Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD (Homologous Recombination Deficiency) Subgroups (Part 1 of Study)

The primary efficacy endpoint of PFS is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST (Response Evaluation Criteria in Solid Tumors), as determined by the investigator or death due to any cause, whichever occurs first. Progression is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions. (NCT01891344)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.

InterventionDays (Median)
Part 1: tBRCA388
Part 1: Non-tBRCA LOH+174
Part 1: Non-tBRCA LOH-160
Part 1: Non-tBRCA LOH Unknown223

[back to top]

Overall Survival (Part 2 of Study)

Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive. (NCT01891344)
Timeframe: All patients in Part 2 were followed for survival, subsequent therapy, and secondary malignancy every 12 weeks until death, loss to follow-up, withdrawal of consent from study or study closure, whichever happened first, up to 7 years.

InterventionMonths (Median)
Part 2: tBRCA22.7
Part 2: Non-tBRCA LOH+14.7
Part 2: Non-tBRCA LOH-13.3
Part 2: Non-tBRCA LOH Unknown14.1

[back to top]

Objective Response Rate (ORR) by RECIST v1.1 in Molecularly-defined HRD Subgroups (Part 2 of Study)

The confirmed response rate by RECIST v1.1 is defined as the percentage of patients with a confirmed complete response (CR) or partial response (PR) on subsequent tumor assessment at least 28 days after first response documentation. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. (NCT01891344)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.

Interventionpercentage of participants (Number)
Part 2: tBRCA31.0
Part 2: Non-tBRCA LOH+6.8
Part 2: Non-tBRCA LOH-5.6
Part 2: Non-tBRCA LOH Unknown13.0

[back to top]

Objective Response Rate (ORR) by RECIST v1.1 and GCIG CA-125 Criteria

The endpoint of ORR defined as the percentage of patients with a best response of CR or PR using RECIST v 1.1 or a response per Gynecologic Cancer InterGroup cancer antigen 125 (GCIG CA-125) criteria. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. A response to CA-125 has occurred if there is at least a 50% decrease from baseline: 1. in a sample collected after initiation of study treatment AND 2. that is confirmed in a subsequent sample collected ≥21 days after the prior sample. The absolute value of this confirmatory sample must be ≤110% of the prior sample. The date when the first sample with a 50% decrease from baseline is observed is the date of the CA-125 response. (NCT01891344)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.

Interventionpercentage of patients (Number)
Part 1: tBRCA87.5
Part 1: Non-tBRCA LOH+46.3
Part 1: Non-tBRCA LOH-21.4
Part 1: Non-tBRCA LOH Unknown50.0
Part 2: tBRCA54.8
Part 2: Non-tBRCA LOH+12.3
Part 2: Non-tBRCA LOH-13.1
Part 2: Non-tBRCA LOH Unknown30.4

[back to top]

Objective Response Rate (ORR) by RECIST v1.1 (Part 1 of Study)

The confirmed response rate by RECIST v1.1 is defined as the percentage of patients with a confirmed CR or PR on subsequent tumor assessment at least 28 days after first response documentation. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. (NCT01891344)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.

Interventionpercentage of participants (Number)
Part 1: tBRCA80.0
Part 1: Non-tBRCA LOH+28.0
Part 1: Non-tBRCA LOH-10.0
Part 1: Non-tBRCA LOH Unknown33.3

[back to top]

Duration of Response Per RECIST v1.1

Duration of response (DOR) for any confirmed RECIST CR or PR measured from the date of the first occurrence of a response until the first occurrence of progressive disease (PD) per RECIST. For patients who continued treatment post-progression, the first date of progression was used for the analysis. Any patients with an ongoing response were censored at the date of the last post-baseline scan. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. (NCT01891344)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years.

InterventionDays (Median)
Part 1: tBRCA281
Part 1: Non-tBRCA LOH+329
Part 1: Non-tBRCA LOH-169
Part 1: Non-tBRCA LOH Unknown225
Part 2: tBRCA176
Part 2: Non-tBRCA LOH+282
Part 2: Non-tBRCA LOH-314
Part 2: Non-tBRCA LOH Unknown181

[back to top]

Disease Progression According to RECIST v1.1, as Assessed by Independent Radiology Review (IRR), or Death From Any Cause (irrPFS)

To evaluate PFS by RECIST v1.1, as assessed by independent radiology review (IRR). (NCT01968213)
Timeframe: Every 12 calendar weeks (within 7 days prior is permitted) after start of treatment until treatment discontinuation due to disease progression. Total follow-up was up to approximately 8.2 years.

Interventionmonths (Median)
Rucaparib 600 mg Tablets13.7
Placebo Tablets5.4

[back to top]

Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS)

Progression-free survival by Investigator (invPFS) is defined as the time from randomization to disease progression, according to RECIST v1.1 criteria as assessed by the investigator, or death due to any cause, whichever occurs first. Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of measurable lesions, an unequivocal increase in existing non-measurable lesion(s), or the appearance of unequivocal new lesion(s). (NCT01968213)
Timeframe: Every 12 calendar weeks (within 7 days prior is permitted) after start of treatment until treatment discontinuation due to disease progression. Total follow-up was up to approximately 3 years.

InterventionMonths (Median)
Rucaparib 600 mg Tablets10.8
Placebo Tablets5.4

[back to top]

Overall Survival (OS)

Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive. (NCT01968213)
Timeframe: All patients were followed for survival up to approximately 8.2 years.

InterventionMonths (Median)
Rucaparib 600 mg Tablets36.0
Placebo Tablets43.2

[back to top] [back to top]

Time to an 8-point Decrease in the Total Score of the FOSI-18

The National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index (FOSI-18) is a questionnaire, for completion by patients, designed to assess the impact of cancer therapy on ovarian cancer-related physical, emotional and treatment-related symptoms, and is based on numerical point scoring of symptoms. The questionnaire is designed to evaluate changes in the total score in individual assessments over time. This study looked at the time to an 8-point reduction in the total score as an indicator of improvement in disease-related symptoms on cancer therapy. (NCT01968213)
Timeframe: Screening, Day 1 of each treatment cycle, Treatment Discontinuation visit, and 28-day Follow-up visit. Total follow-up was up to approximately 6.4 years.

InterventionMonths (Median)
Rucaparib 600 mg Tablets2.9
Placebo Tablets10.8

[back to top]

Individual Model Parameter Estimates of Rucaparib and Covariates Identification

Concentration summary statistics (NCT01968213)
Timeframe: Study data collection occurred over approximately 7 months.

Interventionng/mL (Geometric Mean)
Cycle 2 Day 1Cycle 4 Day 1Cycle 7 Day 1
Rucaparib 600 mg Tablets112811361165

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

,,,
InterventionParticipants (Number)
Solid Tumors
Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg0
Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg1
Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg0
Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni0

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

InterventionParticipants (Number)
Myelofibrosis
Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg0

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

InterventionParticipants (Number)
Multiple Myeloma
Part1/Treatment Group C : 8mg QD INCB0576430

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

InterventionParticipants (Number)
AML
Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg0

[back to top]

Cmax: Maximum Observed Plasma Concentration of INCB057643.

Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fasted state. (NCT02711137)
Timeframe: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8

,,
InterventionnM (Mean)
C1D1C1D8
12mg QD INCB057643266293
16mg QD INCB057643343340
8mg QD INCB057643201210

[back to top]

Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643

Time to maximum plasma concentration of INCB057643 administered as monotherapy in fed state (NCT02711137)
Timeframe: C2D1

Interventionhours (Median)
12mg QD INCB0576436.00

[back to top]

Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.

Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fed state. (NCT02711137)
Timeframe: C2D1

InterventionnM (Mean)
12mg QD INCB057643220

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAE's).

Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment. (NCT02711137)
Timeframe: From screening through at least 30 days after end of treatment, up to approximately 24 months

InterventionParticipants (Number)
Part1/Treatment Group A : 8mg QD INCB0576434
Part1/Treatment Group A : 12mg QD INCB0576435
Part1/Treatment Group A : 16mg QD INCB0576438
Part1/Treatment Group B : 8mg QD INCB0576437
Part1/Treatment Group B : 12mg QD INCB0576435
Part1/Treatment Group C : 8mg QD INCB0576431
Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort86
Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort5
Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg1
Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg2
Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg4
Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni3
Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg1
Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg2

[back to top]

AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643

Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration of INCB057643 administered as monotherapy in fasted state (NCT02711137)
Timeframe: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1

Interventionh*nM (Mean)
8mg QD INCB0576432090
12mg QD INCB0576432550
16mg QD INCB0576433210

[back to top]

AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy

Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fed state. (NCT02711137)
Timeframe: C2D1

Interventionh*nM (Mean)
12mg QD INCB0576432980

[back to top]

AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy

Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fasted state (NCT02711137)
Timeframe: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D8

Interventionh*nM (Mean)
8mg QD INCB0576431940
12mg QD INCB0576432740
16mg QD INCB0576433610

[back to top]

Tmax: Time to Maximum Plasma Concentration of INCB057643

Time to maximum plasma concentration of INCB057643 administered as monotherapy in fasted state (NCT02711137)
Timeframe: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8

,,
Interventionhours (Median)
C1D1C1D8
12mg QD INCB05764322
16mg QD INCB0576432.002.00
8mg QD INCB0576432.001.00

[back to top]

Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay

An ex vivo assay (utilized in monotherapy only), Measuring Total c-Myc protein expressed from an exogenously added cell line (KMS12BM) to patient plasma, before and after administration of INCB057643. (NCT02711137)
Timeframe: PD in plasma at pre-dose and 0.5, 1, 2, 4, 6 and 8 hours postdose, for C1D1 and C1D8, and 24hrs post dose for C1D1

,,
Intervention%Inhibition of Total c-Myc (Mean)
C1D1C1D8
12mg QD INCB0576432843.4
16mg QD INCB0576435465
8mg QD INCB0576432430

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

InterventionParticipants (Number)
Solid TumorsLymphomaGlioblastoma
Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort020

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

,
InterventionParticipants (Number)
AMLMyelodysplastic SyndromeMyelofibrosis
Part1/Treatment Group B : 8mg QD INCB057643000
Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort100

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

,,
InterventionParticipants (Number)
Solid TumorsLymphoma
Part1/Treatment Group A : 12mg QD INCB05764300
Part1/Treatment Group A : 16mg QD INCB05764301
Part1/Treatment Group A : 8mg QD INCB05764301

[back to top]

Objective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response [complete response (CR) or partial response (PR)]. (NCT02711137)
Timeframe: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

InterventionParticipants (Number)
AMLMyelodysplastic Syndrome
Part1/Treatment Group B : 12mg QD INCB05764300

[back to top]

Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 and/or CA-125 Response (Efficacy Population)

A secondary endpoint is ORR for the Treatment Part of the study defined as the percentage of patients with best response of CR or PR using RECIST v1.1 or response per Gynecologic Cancer InterGroup Cancer Antigen 125 (GCIG CA-125) criteria. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Response to CA-125 has occurred if there is at least a 50% decrease from baseline: 1. in a sample collected after initiation of study treatment AND 2. that is confirmed in a subsequent sample collected ≥21 days after the prior sample. The absolute value of this confirmatory sample must be ≤110% of the prior sample. The date when the first sample with a 50% decrease from baseline is observed is the date of the CA-125 response. (NCT02855944)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

Interventionpercentage of patients (Number)
Rucaparib50.7
Chemotherapy43.6

[back to top]

Investigator Assessed Duration of Response (DOR) by RECIST v1.1 (Efficacy Population)

A secondary endpoint is the DOR for the Treatment Part of the study. The DOR as assessed by investigator is analyzed in the subgroup of patients who had a confirmed response by RECIST v1.1. DOR for any confirmed RECIST CR or PR will be measured from the date of the first response until the first date that progressive disease (PD) is documented. DOR is calculated in months as the time from the first date of the scan showing a response to the first scan with disease progression +1 day. Any patients with an ongoing response are censored at the date of the last post-baseline scan. Only tumor scans up to and within 6 weeks of start of any subsequent anti-cancer treatment are included. Progressive disease (PD) is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02855944)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

Interventionmonths (Median)
Rucaparib9.4
Chemotherapy7.2

[back to top]

Investigator Assessed Duration of Response (DOR) by RECIST v1.1 (ITT Population)

A secondary endpoint is the DOR for the Treatment Part of the study. The DOR as assessed by investigator is analyzed in the subgroup of patients who had a confirmed response by RECIST v1.1. DOR for any confirmed RECIST CR or PR will be measured from the date of the first response until the first date that progressive disease (PD) is documented. DOR is calculated in months as the time from the first date of the scan showing a response to the first scan with disease progression +1 day. Any patients with an ongoing response are censored at the date of the last post-baseline scan. Only tumor scans up to and within 6 weeks of start of any subsequent anti-cancer treatment are included. Progressive disease (PD) is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02855944)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

Interventionmonths (Median)
Rucaparib9.4
Chemotherapy7.2

[back to top]

Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 (Efficacy Population)

A secondary endpoint is the ORR for the Treatment Part of the study. ORR is defined as the percentage of patients with a confirmed CR (complete response) or PR (partial response) by RECIST v1.1. The confirmed response is defined as a CR or PR on subsequent tumor assessment at least 28 days after first response documentation. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. (NCT02855944)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

Interventionpercentage of participants (Number)
Rucaparib40.3
Chemotherapy32.3

[back to top]

Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 (ITT Population)

A secondary endpoint is the ORR for the Treatment Part of the study. ORR is defined as the percentage of patients with a confirmed CR (complete response) or PR (partial response) by RECIST v1.1. The confirmed response is defined as a CR or PR on subsequent tumor assessment at least 28 days after first response documentation. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. (NCT02855944)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

Interventionpercentage of participants (Number)
Rucaparib37.9
Chemotherapy30.2

[back to top]

Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 and/or CA-125 Response (ITT Population)

A secondary endpoint is ORR for the Treatment Part of the study defined as the percentage of patients with best response of CR or PR using RECIST v1.1 or response per Gynecologic Cancer InterGroup Cancer Antigen 125 (GCIG CA-125) criteria. Complete response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Response to CA-125 has occurred if there is at least a 50% decrease from baseline: 1. in a sample collected after initiation of study treatment AND 2. that is confirmed in a subsequent sample collected ≥21 days after the prior sample. The absolute value of this confirmatory sample must be ≤110% of the prior sample. The date when the first sample with a 50% decrease from baseline is observed is the date of the CA-125 response. (NCT02855944)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

Interventionpercentage of patients (Number)
Rucaparib47.8
Chemotherapy40.5

[back to top]

Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population)

The primary efficacy endpoint is invPFS for the Treatment Part of the study. The time to invPFS is calculated in months as the time from randomization to disease progression +1 day, as determined by RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) criteria or death due to any cause, whichever occurs first. Progression is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02855944)
Timeframe: Assessments every 8 weeks from Cycle 1 Day 1 (C1D1) until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

InterventionMonths (Median)
Rucaparib7.4
Chemotherapy5.7

[back to top]

Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population)

The primary efficacy endpoint is invPFS for the Treatment Part of the study. The time to invPFS is calculated in months as the time from randomization to disease progression +1 day, as determined by RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) criteria or death due to any cause, whichever occurs first. Progression is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02855944)
Timeframe: Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.

InterventionMonths (Median)
Rucaparib7.4
Chemotherapy5.7

[back to top]

Least Squares Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for the First 6 Cycles (Efficacy Population)

EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer patients. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. Mean changes from baseline global score over the first 6 cycles in the Treatment Part of the study were analyzed. (NCT02855944)
Timeframe: Baseline to the end of Cycle 6, or up to approximately 6 months

Interventionscore on a scale (Least Squares Mean)
Rucaparib0.5
Chemotherapy0.3

[back to top]

Least Squares Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for the First 6 Cycles (ITT Population)

EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer patients. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. Mean changes from baseline global score over the first 6 cycles in the Treatment Part of the study were analyzed. (NCT02855944)
Timeframe: Baseline to the end of Cycle 6, or up to approximately 6 months

Interventionscore on a scale (Least Squares Mean)
Rucaparib0.6
Chemotherapy0.4

[back to top]

Overall Survival (Efficacy Population)

Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive. (NCT02855944)
Timeframe: All patients were followed for survival up to approximately 3.5 years.

InterventionMonths (Median)
Rucaparib21.1
Chemotherapy26.2

[back to top]

Overall Survival (ITT Population)

Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive. (NCT02855944)
Timeframe: All patients were followed for survival up to approximately 3.5 years.

InterventionMonths (Median)
Rucaparib19.4
Chemotherapy25.4

[back to top]

Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

The number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal. (NCT02935634)
Timeframe: From first dose to 100 days after last dose of study therapy (approximately 30 months)

,,,,,,,,,,,
InterventionParticipants (Count of Participants)
TSH > ULNTSH > ULN WITH TSH <= ULN AT BASELINETSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLNTSH > ULN WITH FT3/FT4 TEST MISSINGTSH < LLNTSH = LLN AT BASELINETSH ULNTSH TSH < LLN WITH FT3/FT4 TEST MISSING
Track 1: Ipilimumab + Rucaparib1110000000
Track 1: Nivolumab + BMS-9860164321121020
Track 1: Nivolumab + BMS-9862056421353212
Track 1: Nivolumab + Ipilimumab4311210100
Track 1: Nivolumab + Ipilimumab + Rucaparib1110000000
Track 1: Nivolumab + Rucaparib1001000000
Track 2: Ipilimumab + Rucaparib1100100000
Track 2: Nivolumab + BMS-9860165122165204
Track 2: Nivolumab + BMS-9862055420300000
Track 2: Nivolumab + Ipilimumab11653343310
Track 2: Nivolumab + Ipilimumab + Rucaparib1010000000
Track 2: Nivolumab + Rucaparib0000000000

[back to top]

Number of Participants With Laboratory Abnormalities in Specific Liver Tests

The number of participants with laboratory abnormalities in specific liver tests based on US conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal (NCT02935634)
Timeframe: From first dose to 100 days after last dose of study therapy (approximately 30 months)

,,,,,,,,,,,
InterventionParticipants (Count of Participants)
ALT OR AST > 3XULNALT OR AST> 5XULNALT OR AST> 10XULNALT OR AST > 20XULNTOTAL BILIRUBIN > 2XULNALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAYALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS
Track 1: Ipilimumab + Rucaparib2100111
Track 1: Nivolumab + BMS-9860166210322
Track 1: Nivolumab + BMS-9862055321000
Track 1: Nivolumab + Ipilimumab6320222
Track 1: Nivolumab + Ipilimumab + Rucaparib1100111
Track 1: Nivolumab + Rucaparib1000111
Track 2: Ipilimumab + Rucaparib1110000
Track 2: Nivolumab + BMS-9860162100100
Track 2: Nivolumab + BMS-9862052000300
Track 2: Nivolumab + Ipilimumab6431322
Track 2: Nivolumab + Ipilimumab + Rucaparib0000000
Track 2: Nivolumab + Rucaparib3000111

[back to top]

Number of Participants With AEs, SAEs, AEs Leading to Discontinuation, and Death

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization. (NCT02935634)
Timeframe: From first dose to 100 days after last dose of study therapy (assessed up to approximately 30 months)

,,,,,,,,,,,
InterventionParticipants (Number)
Adverse Events (AEs)Serious Adverse Events (SAEs)AEs Leading to DiscontinuationDeath
Track 1: Ipilimumab + Rucaparib8645
Track 1: Nivolumab + BMS-9860162015715
Track 1: Nivolumab + BMS-98620538241126
Track 1: Nivolumab + Ipilimumab2319919
Track 1: Nivolumab + Ipilimumab + Rucaparib6444
Track 1: Nivolumab + Rucaparib7537
Track 2: Ipilimumab + Rucaparib2212
Track 2: Nivolumab + BMS-9860163624826
Track 2: Nivolumab + BMS-9862052212213
Track 2: Nivolumab + Ipilimumab23171019
Track 2: Nivolumab + Ipilimumab + Rucaparib4303
Track 2: Nivolumab + Rucaparib6403

[back to top]

Objective Response Rate (ORR) by Investigator

ORR is the percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to <10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method. (NCT02935634)
Timeframe: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (up to approximately 65 months)

InterventionPercent of participants (Number)
Track 1: Nivolumab + Ipilimumab4.3
Track 1: Nivolumab + BMS-9860165.0
Track 1: Nivolumab + BMS-98620513.2
Track 1: Nivolumab + Rucaparib0
Track 1: Ipilimumab + Rucaparib0
Track 1: Nivolumab + Ipilimumab + Rucaparib16.7
Track 2: Nivolumab + Ipilimumab8.7
Track 2: Nivolumab + BMS-9860165.6
Track 2: Nivolumab + BMS-9862050
Track 2: Nivolumab + Rucaparib0
Track 2: Ipilimumab + Rucaparib0
Track 2: Nivolumab + Ipilimumab + Rucaparib0

[back to top]

Kaplan-Meier Analysis of Progression Free Survival Rate (PFSR) at 24 Weeks

The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula. (NCT02935634)
Timeframe: 24 weeks after first dose

InterventionProportion of participants (Number)
Track 1: Nivolumab + IpilimumabNA
Track 1: Nivolumab + BMS-986016NA
Track 1: Nivolumab + BMS-9862050.240
Track 1: Nivolumab + RucaparibNA
Track 1: Ipilimumab + RucaparibNA
Track 1: Nivolumab + Ipilimumab + RucaparibNA
Track 2: Nivolumab + IpilimumabNA
Track 2: Nivolumab + BMS-9860160.170
Track 2: Nivolumab + BMS-986205NA
Track 2: Nivolumab + RucaparibNA
Track 2: Ipilimumab + RucaparibNA
Track 2: Nivolumab + Ipilimumab + RucaparibNA

[back to top]

Median Duration of Response (DOR)

Duration of Response (DOR) is the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method. (NCT02935634)
Timeframe: From first dose to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 65 months)

InterventionWeeks (Median)
Track 1: Nivolumab + Ipilimumab156.0
Track 1: Nivolumab + BMS-986016NA
Track 1: Nivolumab + BMS-986205NA
Track 1: Nivolumab + Ipilimumab + RucaparibNA
Track 2: Nivolumab + Ipilimumab14.71
Track 2: Nivolumab + BMS-98601616.86

[back to top]

Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR)

The primary efficacy endpoint is confirmed radiographic ORR by central IRR. ORR is defined as the percentage of patients with a confirmed CR (complete response) or PR (partial response) by mRECIST (modified Response Evaluation Criteria in Solid Tumors) v1.1/PCWG3 (Prostate Cancer Working Group 3) criteria. The confirmed response is defined as a CR or PR on subsequent tumor assessment at least 28 days after first response documentation in the absence of confirmed progression in bone. CR is disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

Interventionpercentage of participants (Number)
BRCA Mutation45.7
ATM Mutation0.0
CDK12 Mutation0.0
CHEK2 Mutation0.0
Other Gene Mutation41.2

[back to top]

Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Investigator (INV)

A supportive efficacy endpoint is confirmed radiographic ORR by INV. ORR is defined as the percentage of patients with a confirmed CR (complete response) or PR (partial response) by mRECIST (modified Response Evaluation Criteria in Solid Tumors) v1.1/PCWG3 (Prostate Cancer Working Group 3) criteria. The confirmed response is defined as a CR or PR on subsequent tumor assessment at least 28 days after first response documentation in the absence of confirmed progression in bone. CR is disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

Interventionpercentage of participants (Number)
BRCA Mutation48.3
ATM Mutation9.5
CDK12 Mutation0.0
CHEK2 Mutation25.0
Other Gene Mutation41.2

[back to top]

Confirmed PSA Response (≥ 50% Decrease) by Gene as Assessed by Local Laboratory

A secondary endpoint is confirmed PSA (prostate-specific antigen) response (≥ 50% reduction) as assessed by local laboratory. Confirmed PSA response is analyzed for all patients who had PSA value at baseline and is defined as the percentage of patients having 2 consecutive PSA values (at least 3 weeks apart) that are at least 50% lower than baseline and that occur prior to PSA progression. PSA progression is defined as a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir in PSA. (NCT02952534)
Timeframe: PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.

Interventionpercentage of participants (Number)
BRCA Mutation53.5
ATM Mutation3.4
CDK12 Mutation7.1
CHEK2 Mutation14.3
Other Gene Mutation36.0

[back to top]

Confirmed PSA Response (≥ 90% Decrease) by Gene as Assessed by Local Laboratory

A secondary endpoint is confirmed PSA (prostate-specific antigen) response (≥ 90% reduction) as assessed by local laboratory. Confirmed PSA response is analyzed for all patients who had PSA value at baseline and is defined as the percentage of patients having 2 consecutive PSA values (at least 3 weeks apart) that are at least 90% lower than baseline and that occur prior to PSA progression. PSA progression is defined as a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir in PSA. (NCT02952534)
Timeframe: PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.

Interventionpercentage of participants (Number)
BRCA Mutation19.8
ATM Mutation0
CDK12 Mutation0
CHEK2 Mutation14.3
Other Gene Mutation16.0

[back to top]

Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Central Independent Radiology Review (IRR)

A secondary efficacy endpoint is DOR by central IRR. The DOR is defined as the time from the date that a confirmed response per modified RECIST Version 1.1/PCWG3 is first reported to the time that progressive disease (PD) is first documented. Progressive disease is defined using RECIST v1.1, as at least a 20% increase in the sum of the diameters of target lesions, or an unequivocal increase in non-target lesions, or the appearance of new lesions. PCWG3 criteria is used to document evidence of disease progression in bone lesions. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

Interventionmonths (Median)
BRCA Mutation15.5
Other Gene Mutation22.1

[back to top]

Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Investigator

A secondary efficacy endpoint is DOR as assessed by the investigator. The DOR is defined as the time from the date that a confirmed response per modified RECIST Version 1.1/PCWG3 is first reported to the time that progressive disease (PD) is first documented. Progressive disease is defined using RECIST v1.1, as at least a 20% increase in the sum of the diameters of target lesions, or an unequivocal increase in non-target lesions, or the appearance of new lesions. PCWG3 criteria is used to document evidence of disease progression in bone lesions. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

Interventionmonths (Median)
BRCA Mutation6.6
ATM Mutation7.5
CHEK2 Mutation16.6
Other Gene Mutation18.4

[back to top]

Overall Survival (OS) by Gene

A secondary efficacy endpoint is Overall Survival (OS). OS is defined as the date from first dose of rucaparib to the date of death due to any cause, +1 day. (NCT02952534)
Timeframe: From date of first dose until event, loss to follow-up, withdrawal of consent, or study closure: an overall median of approximately 33.1 months

Interventionmonths (Median)
BRCA Mutation17.2
ATM Mutation14.6
CDK12 Mutation13.9
CHEK2 Mutation11.1
Other Gene Mutation11.6

[back to top]

Radiologic Progression-free Survival (rPFS) by Gene in All Patients Per Central Independent Radiology Review (IRR)

A secondary efficacy endpoint is Radiologic Progression-free Survival (rPFS) assessed by IRR. rPFS is defined as the time from first dose of rucaparib to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first, plus 1 day. Radiographic disease progression includes confirmed bone disease progression and soft tissue disease progression adjudicated by IRR using the PCWG3 guidelines for bone disease and modified RECIST Version 1.1 for soft tissue disease. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

Interventionmonths (Median)
BRCA Mutation10.7
ATM Mutation5.3
CDK12 Mutation3.7
CHEK2 Mutation9.4
Other Gene Mutation11.6

[back to top]

Radiologic Progression-free Survival (rPFS) by Gene in All Patients Per Investigator

A secondary efficacy endpoint is Radiologic Progression-free Survival (rPFS) assessed by Investigator. rPFS is defined as the time from first dose of rucaparib to the date of first objective evidence of radiographic progression (soft tissue or bone lesion) or death due to any cause, whichever occurs first, plus 1 day. Radiographic disease progression includes confirmed bone disease progression and soft tissue disease progression using the PCWG3 guidelines for bone disease and modified RECIST Version 1.1 for soft tissue disease. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

Interventionmonths (Median)
BRCA Mutation9.6
ATM Mutation7.8
CDK12 Mutation3.7
CHEK2 Mutation3.5
Other Gene Mutation11.6

[back to top]

Clinical Benefit Rate (CBR) by Gene Per Central Independent Radiology Review (IRR)

A secondary efficacy endpoint is Clinical Benefit Rate (CBR) assessed by IRR. CBR is defined as the number of patients without radiographic progression (defined by modified RECIST Version 1.1/ PCWG3 criteria) who were continuing with study drug treatment through the given time interval divided by the number of patients who had the given amount of follow-up. Clinical benefit rates are summarized at 6 and 12 months. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

,,,,
InterventionParticipants (Count of Participants)
6 months12 months
ATM Mutation103
BRCA Mutation10036
CDK12 Mutation20
CHEK2 Mutation21
Other Gene Mutation136

[back to top]

Clinical Benefit Rate (CBR) by Gene Per Investigator

A secondary efficacy endpoint is Clinical Benefit Rate (CBR) assessed by Investigator. CBR is defined as the number of patients without radiographic progression (defined by modified RECIST Version 1.1/ PCWG3 criteria) who were continuing with study drug treatment through the given time interval divided by the number of patients who had the given amount of follow-up. Clinical benefit rates are summarized at 6 and 12 months. (NCT02952534)
Timeframe: Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.

,,,,
InterventionParticipants (Count of Participants)
6 months12 months
ATM Mutation176
BRCA Mutation10339
CDK12 Mutation31
CHEK2 Mutation21
Other Gene Mutation146

[back to top]

Steady State Trough (Cmin) Level Rucaparib Concentrations

Trough (Cmin) concentrations of rucaparib are summarized for all patients with at least one PK sample collected. The absolute values of rucaparib plasma concentration at each time point are presented by gene. (NCT02952534)
Timeframe: Participants were assessed at Study Day 29, Day 57, Day 85 and Day 113

,,,,
Interventionng/mL (Median)
Day 29Day 57Day 85Day 113
ATM Mutation1605.0021600.3801505.4001515.300
BRCA Mutation1539.5651578.3531308.7041533.690
CDK12 Mutation1639.3571405.1671699.7001520.700
CHEK2 Mutation1286.9981841.667815.500728.000
Other Gene Mutation1189.8451792.4992255.8891433.875

[back to top]

Time to PSA Progression by Gene

A secondary efficacy endpoint is time to PSA progession. Time to PSA progression is defined as the time from first dose of rucaparib to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline if there was no PSA decline after baseline) in PSA was measured, plus 1 day. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later (unless the PSA progression occurred at the last recorded PSA assessment). If confirmed, the date used for time of PSA progression is the earlier of the 2 PSA dates. (NCT02952534)
Timeframe: PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.

Interventionmonths (Median)
BRCA Mutation6.5
ATM Mutation3.1
CDK12 Mutation3.5
CHEK2 Mutation5.6
Other Gene Mutation5.3

[back to top]

Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA Alteration

"The primary efficacy endpoint for the study is rPFSirr, defined as the time from randomization to the first objective evidence of radiographic progression, or death due to any cause (whichever occurs first).~Radiographic disease progression includes confirmed soft tissue disease progression and confirmed bone disease progression as per modified RECIST Version 1.1 (at least a 20% increase in the sum of the LD of target lesions or appearance of one or more new extra-skeletal lesions and/or unequivocal progression of existing nontarget lesions) or PCWG3 criteria Progression by bone is determined by PCWG3 criteria in which at least two new lesions appearing during the first 12-week flare window followed by 2 additional new lesions in the confirmatory scan appearing after the 12-week flare window, or after the 12-week flare window, at least 2 new lesions relative to the first post-treatment scan confirmed on a subsequent scan)." (NCT02975934)
Timeframe: From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)

Interventionmonths (Median)
Rucaparib11.2
Abiraterone Acetate or Enzalutamide or Docetaxel6.4

[back to top]

Change in Patient-reported Outcome (PRO) in Participants With a BRCA Alteration: EQ-5D-5L

Changes in health and pain status from baseline to week 25 using: EuroQol-5D-5L Visual Analogue Scale (EQ-5D-5L VAS; on a scale from 100 to 0, from best to worst health status). The greater the increase in score (including more negative) from baseline to week 25 the greater the increase in health status. Assessments completed during screening, at study treatment visits (Day 1, Day 15, Day 29, Day 43, Day 57, and every 29 days thereafter) during the Treatment Phase, the Treatment Discontinuation Visit, and during the Follow-up Phase. (NCT02975934)
Timeframe: From enrollment to up to approximately 25 weeks

Interventionunits on a scale (Least Squares Mean)
Rucaparib2.4
Abiraterone Acetate or Enzalutamide or Docetaxel1.8

[back to top]

Change in Patient-reported Outcome (PRO) in Participants With a BRCA Alteration: FACT-P

Changes in health and pain status from baseline to week 25 using: Functional Assessment of Cancer Therapy-Prostate questionnaire (FACT-P total score, on a scale of 0 to 156 where a higher score is better quality of life). The greater the decrease in score (ie more negative) from baseline to week 25 the greater the decrease in health status. Assessments completed during screening, at study treatment visits (Day 1, Day 15, Day 29, Day 43, Day 57, and every 29 days thereafter) (during the Treatment Phase, the Treatment Discontinuation Visit, and during the Follow-up Phase. (NCT02975934)
Timeframe: From enrollment to up to approximately 25 weeks

Interventionunits on a scale (Least Squares Mean)
Rucaparib-0.8
Abiraterone Acetate or Enzalutamide or Docetaxel-3.9

[back to top]

Clinical Benefit Rate (CBR) by IRR at 6 Months in Participants With a BRCA Alteration

Defined as the percentage of participants with a complete response (CR), partial response (PR), and stable disease (SD) according to modified RECIST Version 1.1 with no progression in bone per PCWG3 criteria. (NCT02975934)
Timeframe: From enrollment to 6 months

Interventionpercentage of participants (Number)
Rucaparib63.0
Abiraterone Acetate or Enzalutamide or Docetaxel22.7

[back to top]

Clinical Benefit Rate (CBR) by IRR at 6 Months in Participants With a BRCA or ATM Alteration Combined

Defined as the percentage of participants with a Complete Response (CR), Partial Response (PR), and Stable Disease (SD), according to Modified RECIST Version 1.1 with no progression in bone per PCWG3 Criteria. (NCT02975934)
Timeframe: From enrollment to 6 months

Interventionpercentage of participants (Number)
Rucaparib57.6
Abiraterone Acetate or Enzalutamide or Docetaxel25.4

[back to top]

Duration of Response (DOR) by IRR in Participants With a BRCA Alteration

DOR is defined as the time from the first confirmed response (CR or PR by modified RECIST Version 1.1 in participants with nodal or visceral ± nodal disease) until the first date that Progressive Disease (PD) (using the same criteria) is documented. (NCT02975934)
Timeframe: From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)

Interventionmonths (Median)
Rucaparib7.4
Abiraterone Acetate or Enzalutamide or Docetaxel7.4

[back to top]

Duration of Response (DOR) by IRR in Participants With a BRCA or ATM Alteration Combined

DOR is defined as the time from the first confirmed response (CR or PR by modified RECIST Version 1.1 in participants with nodal or visceral ± nodal disease) until the first date that Progressive Disease (PD) (using the same criteria) is documented. (NCT02975934)
Timeframe: From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)

Interventionmonths (Median)
Rucaparib7.4
Abiraterone Acetate or Enzalutamide or Docetaxel7.4

[back to top]

Interim Overall Survival in Participants With a BRCA Alteration

Overall survival time is calculated as the time from randomization to death (by any cause) +1 day. Participants who have not died will be censored on the date the participant was last known to be alive. (NCT02975934)
Timeframe: From enrollment to primary completion of study (up to approximately 5 years)

Interventionmonths (Median)
Rucaparib24.3
Abiraterone Acetate or Enzalutamide or Docetaxel20.8

[back to top]

Interim Overall Survival in Participants With a BRCA or ATM Alteration Combined

Overall survival time is calculated as the time from randomization to death (by any cause) +1 day. Participants who have not died will be censored on the date the participants was last known to be alive. (NCT02975934)
Timeframe: From enrollment to primary completion of study (up to approximately 5 years)

Interventionmonths (Median)
Rucaparib23.6
Abiraterone Acetate or Enzalutamide or Docetaxel20.9

[back to top]

Objective Response Rate (ORR) by IRR in Participants With a BRCA Alteration

"ORR is defined as the percentage of participants with a confirmed best response of Complete response (CR) or Partial Response (PR) in participants with measurable disease at study entry. Modified RECIST Version 1.1 criteria is used to determine ORR (ie, CR or PR by IRR assessment and no progression in bone per PCWG3 by IRR assessment).~CR is disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters." (NCT02975934)
Timeframe: From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)

InterventionParticipants (Count of Participants)
Rucaparib37
Abiraterone Acetate or Enzalutamide or Docetaxel7

[back to top]

Objective Response Rate (ORR) by IRR in Participants With a BRCA or ATM Alteration Combined

"ORR is defined as the percentage of participants with a confirmed best response of Complete response (CR) or Partial Response (PR) in participants with measurable disease at study entry. Modified RECIST Version 1.1 criteria is used to determine ORR (ie, CR or PR by IRR assessment and no progression in bone per PCWG3 by IRR assessment).~CR is disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters." (NCT02975934)
Timeframe: From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)

InterventionParticipants (Count of Participants)
Rucaparib37
Abiraterone Acetate or Enzalutamide or Docetaxel9

[back to top]

PSA Response in Participants With a BRCA Alteration

Confirmed PSA response is defined as ≥ 50% reduction in PSA from baseline on at least two assessments conducted at least 3 weeks apart. PSA response is calculated for all participants with PSA values at baseline and at least one post-baseline assessment. PSA is assessed by a local laboratory. (NCT02975934)
Timeframe: From enrollment to primary completion of study (up to approximately 5 years)

Interventionpercentage of participants (Number)
Rucaparib54.7
Abiraterone Acetate or Enzalutamide or Docetaxel26.7

[back to top]

PSA Response in Participants With a BRCA or ATM Alteration Combined

Confirmed PSA response is defined as ≥ 50% reduction in PSA from baseline on at least two assessments conducted at least 3 weeks apart. PSA response is calculated for all participants with PSA values at baseline and at least one post-baseline assessment. PSA is assessed by a local laboratory. (NCT02975934)
Timeframe: From enrollment to primary completion of study (up to approximately 5 years)

Interventionpercentage of participants (Number)
Rucaparib41.9
Abiraterone Acetate or Enzalutamide or Docetaxel26.7

[back to top]

Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA or ATM Alteration Combined

"The primary efficacy endpoint for the study is rPFSirr, defined as the time from randomization to the first objective evidence of radiographic progression, or death due to any cause (whichever occurs first).~Radiographic disease progression includes confirmed soft tissue disease progression and confirmed bone disease progression as per modified RECIST Version 1.1 (at least a 20% increase in the sum of the LD of target lesions or appearance of one or more new extra-skeletal lesions and/or unequivocal progression of existing nontarget lesions) or PCWG3 criteria (Progression by bone is determined by PCWG3 criteria in which at least two new lesions appearing during the first 12-week flare window followed by 2 additional new lesions in the confirmatory scan appearing after the 12-week flare window, or after the 12-week flare window, at least 2 new lesions relative to the first post-treatment scan confirmed on a subsequent scan)." (NCT02975934)
Timeframe: From enrollment to primary completion of study (Total follow-up was up to approximately 4 years)

Interventionmonths (Median)
Rucaparib10.2
Abiraterone Acetate or Enzalutamide or Docetaxel6.4

[back to top]

Time to Prostate Specific Antigen (PSA) Progression in Participants With a BRCA Alteration

Time to PSA progression is defined as the time from randomization to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline value for participants who did not have a decline in PSA) in PSA was measured. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later. (NCT02975934)
Timeframe: From enrollment to primary completion of study (up to approximately 5 years)

Interventionmonths (Median)
Rucaparib6.6
Abiraterone Acetate or Enzalutamide or Docetaxel3.8

[back to top]

Time to Prostate Specific Antigen (PSA) Progression in Participants With a BRCA or ATM Alteration Combined

Time to PSA progression is defined as the time from randomization to the date that a ≥ 25% increase and absolute increase of ≥ 2 ng/mL above the nadir (or baseline value for participants who did not have a decline in PSA) in PSA was measured. The increase must be confirmed by a second consecutive assessment conducted at least 3 weeks later. (NCT02975934)
Timeframe: From enrollment to primary completion of study (up to approximately 5 years)

Interventionmonths (Median)
Rucaparib5.7
Abiraterone Acetate or Enzalutamide or Docetaxel3.6

[back to top]

Trough Plasma PK (Cmin) of Rucaparib Based on Sparse Sampling

Mean trough PK plasma concentration over time in the safety population with at least one PK sample collected at timepoints week 5, 9, 13 and 17; only Week 5 data presented. (NCT02975934)
Timeframe: From enrollment to week 5 of dosing

Interventionng/mL (Median)
Rucaparib1310

[back to top]

Change in Patient-reported Outcome (PRO) in Participants With a BRCA Alteration: BPI-SF

Changes in health and pain status from baseline to week 25 using: Brief Pain Inventory-Short Form (BPI-SF) questionnaire (on a scale of 1 to 10, from mild to severe, for pain and pain-interference scores). A decrease indicates less severe pain/interference. Assessments completed during screening, at study treatment visits (Day 1, Day 15, Day 29, Day 43, Day 57, and every 29 days thereafter) (during the Treatment Phase, the Treatment Discontinuation Visit, and during the Follow-up Phase. (NCT02975934)
Timeframe: From enrollment to up to approximately 25 weeks

,
Interventionunits on a scale (Mean)
BPI-SF Pain ScoreBPI-SF Interference Score
Abiraterone Acetate or Enzalutamide or Docetaxel0.140.65
Rucaparib-0.32-0.28

[back to top]

Duration of Response (DOR)

Time from initial response to progression or death from any cause (NCT03140670)
Timeframe: 24 months

InterventionMonths (Median)
Single Arm17.3

[back to top]

Overall Response Rate (ORR)

Confirmed Complete Response or Partial Response according to RECIST v1.1. Complete Response (CR) is defined as tumor burden reduced to 0.0 mm or lymph node lesions are smaller than 10mm. Partial Response (PR), tumor burden decreased by greater than 30% but not CR. Overall Response Rate (ORR) is defined as confirmed CR or PR. (NCT03140670)
Timeframe: 24 months

InterventionPercentage of participants (Number)
Single Arm41.7

[back to top]

Progression-Free Survival (PFS) at 6 Months (PFS6)

Time from initiation of rucaparib until progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Only if absolute increase is equal to or greater than 5mm. (NCT03140670)
Timeframe: 6 months

InterventionPercentage of participants (Number)
Single Arm59.5

[back to top] [back to top]

Overall Survival

Time from initiation of rucaparib until death or last follow-up (NCT03140670)
Timeframe: 24 months

InterventionMonths (Median)
Single Arm23.5

[back to top]

Disease Control Rate (DCR)

Confirmed complete response, partial response, or stable disease lasting for at least 16 weeks (NCT03140670)
Timeframe: 24 months

InterventionPercentage of evaluable patients (Number)
Single Arm66.7

[back to top]

Number of Participants With Laboratory Abnormalities in Specific Liver Tests

"Number of participants with laboratory abnormalities in specific liver tests based on SI conventional units to assess the overall safety and tolerability of BMS-986213 in combination with chemotherapy vs. Nivolumab in combination with chemotherapy. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized:~ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN~Total bilirubin > 2 x ULN~ALP > 1.5 x ULN~Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN~Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN~Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN~Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN" (NCT03338790)
Timeframe: From first dose to up to 30 days post last dose (up to 34 months)

,,,
InterventionParticipants (Number)
ALT or AST > 3xULNALT or AST > 5xULNALT or AST > 10xULNALT or AST > 20xULNTOTAL BILIRUBIN > 2xULNALP > 1.5xULNConcurrent ALT or AST elevation > 3xULN with total Bilirubin > 1.5xULN within one dayConcurrent ALT or AST elevation > 3xULN with total Bilirubin > 1.5xULN within 30 daysConcurrent ALT or AST elevation > 3xULN with total Bilirubin > 2xULN within one dayConcurrent ALT or AST elevation > 3xULN with total Bilirubin > 2xULN within 30 days
Arm A11911203493422
Arm A22314511341111
Arm B63111340000
Arm C43000211100

[back to top]

Number of Deaths

Number of deaths in all treated participants (NCT03338790)
Timeframe: Up to 36 months

InterventionDeaths (Number)
Arm A159
Arm A242
Arm B44
Arm C28

[back to top]

Number of Participants With Laboratory Values Change From Baseline

Number of participants changed from baseline in laboratory values of worst toxicity grade (grade 0= wnl, grade 1= mild, grade 2= moderate, grade 3= severe) based on US conventional units by cohort (NCT03338790)
Timeframe: From first dose to up to 30 days post last dose (Up to 34 months)

,
InterventionParticipants (Number)
Hemoglobin Grade 0Hemoglobin Grade 1Hemoglobin Grade 2Platelet Grade 0Platelet Grade 1Leukocytes Grade 0Leukocytes Grade 1Leukocytes Grade 2Lymphocytes Grade 0Lymphocytes Grade 1Lymphocytes Grade 2Lymphocytes Grade 3Neutrophil Grade 0Neutrophil Grade 1Alkaline Phosphatase Grade 0Alkaline Phosphatase Grade 1Alkaline Phosphatase Grade 2Alkaline Phosphatase Grade 3Aspartate Aminotransferase Grade 0Aspartate Aminotransferase Grade 1Alanine Aminotransferase Grade 0Alanine Aminotransferase Grade 1Bilirubin Grade 0Creatinine Grade 0Creatinine Grade 1
Arm A2212833213460308302643341349448312305
Arm B302021002841280503711313202861332135

[back to top]

Number of Participants With Adverse Events (AEs)

Number of Participants with any grade adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and immune-mediated AEs using the Common Toxicity Criteria Grade for Adverse Events (CTCAE V4) (NCT03338790)
Timeframe: From first dose to up to 30 days post last dose (Up to 34 months)

,,,
InterventionParticipants (Number)
Adverse Events (AEs)Serious Adverse Events (SAEs)AEs leading to discontinuationImmune-mediated AEs (Pneumonitis)Immune-mediated AEs (Diarrhea/Colitis)Immune-mediated AEs (Hepatitis)Immune-mediated AEs (Nephritis/Renal Dysfunction)Immune-mediated AEs (Rash)Immune-mediated AEs (Hypersensitivity/Infusion Reactions)
Arm A1884739148250
Arm A2713726247351
Arm B834133813091
Arm C4920180020103

[back to top]

Prostate-Specific Antigen Response Rate (RR-PSA)

Prostate-specific antigen response rate (RR-PSA) is the percentage of treated participants with a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result (NCT03338790)
Timeframe: Up to approximately 36 months

,,,
InterventionPercentage of participants (Number)
OverallHomologous Recombination Deficiency (HRD+)
Arm A111.918.2
Arm A227.341.9
Arm B46.950.0
Arm C34.150.0

[back to top]

Objective Response Rate Per Prostate Cancer Clinical Trials Working Group 3 (ORR-PCWG3)

Objective response rate per prostate cancer clinical trials working group 3 (ORR-PCWG3) for target lesions and assessed by MRI is the percentage of participants who have a confirmed complete or partial best overall response (BOR) per PCWG3 among treated participants who have measurable disease (NCT03338790)
Timeframe: Up to approximately 36 months

,,,
InterventionPercentage of participants (Number)
OverallHomologous Recombination Deficiency (HRD+)
Arm A110.317.2
Arm A215.425.0
Arm B40.036.8
Arm C11.120.0

[back to top]

Number of Participants With Laboratory Values Change From Baseline

Number of participants changed from baseline in laboratory values of worst toxicity grade (grade 0= wnl, grade 1= mild, grade 2= moderate, grade 3= severe) based on US conventional units by cohort (NCT03338790)
Timeframe: From first dose to up to 30 days post last dose (Up to 34 months)

InterventionParticipants (Number)
Hemoglobin Grade 0Hemoglobin Grade 1Hemoglobin Grade 2Platelet Grade 0Platelet Grade 1Leukocytes Grade 0Leukocytes Grade 1Leukocytes Grade 2Lymphocytes Grade 0Lymphocytes Grade 1Lymphocytes Grade 2Lymphocytes Grade 3Neutrophil Grade 0Neutrophil Grade 1Neutrophil Grade 2Alkaline Phosphatase Grade 0Alkaline Phosphatase Grade 1Alkaline Phosphatase Grade 2Alkaline Phosphatase Grade 3Aspartate Aminotransferase Grade 0Aspartate Aminotransferase Grade 1Alanine Aminotransferase Grade 0Alanine Aminotransferase Grade 1Bilirubin Grade 0Bilirubin Grade 1Creatinine Grade 0Creatinine Grade 1
Arm A12338835438101241031353125139152547441307

[back to top]

Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests

"Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized:~TSH value > ULN and~with baseline TSH value <= ULN~with at least one FT3/FT4 test value < LLN within 2-week window after the abnormal TSH test~with all FT3/FT4 test values >= LLN within 2-week window after the abnormal TSH test~with FT3/FT4 missing within 2-week window after the abnormal TSH test.~TSH < LLN and~with baseline TSH value >= LLN~with at least one FT3/FT4 test value > ULN within 2-week window after the abnormal TSH test~with all FT3/FT4 test values <= ULN within 2-week window after the abnormal TSH test~with FT3/FT4 missing within 2-week window after the abnormal TSH test" (NCT03338790)
Timeframe: From first dose to up to 30 days post last dose (Up to 34 months)

,,,
InterventionParticipants (Number)
TSH > ULNTSH > ULN with TSH <= ULN at baselineTSH > ULN with at least one FT3/FT4 test value < LLNTSH > ULN with all other FT3/FT4 test values >= LLNTSH > ULN with FT3/FT4 test missingTSH < LLNTSH < LLN with TSH >= LLN at baselineTSH < LLN with at least one FT3/FT4 test value > ULNTSH < LLN with all other FT3/FT4 test values <= ULNTSH < LLN with FT3/FT4 test missing
Arm A12217101021613583
Arm A217126921211543
Arm B127732251921112
Arm C1712510288701

[back to top]

Number of Participants With Laboratory Values Change From Baseline

Number of participants changed from baseline in laboratory values of worst toxicity grade (grade 0= wnl, grade 1= mild, grade 2= moderate, grade 3= severe) based on US conventional units by cohort (NCT03338790)
Timeframe: From first dose to up to 30 days post last dose (Up to 34 months)

InterventionParticipants (Number)
Hemoglobin Grade 0Hemoglobin Grade 1Hemoglobin Grade 2Platelet Grade 0Platelet Grade 1Leukocytes Grade 0Leukocytes Grade 1Lymphocytes Grade 0Lymphocytes Grade 1Lymphocytes Grade 2Neutrophil Grade 0Neutrophil Grade 2Alkaline Phosphatase Grade 0Alkaline Phosphatase Grade 1Alkaline Phosphatase Grade 2Alkaline Phosphatase Grade 3Aspartate Aminotransferase Grade 0Aspartate Aminotransferase Grade 1Alanine Aminotransferase Grade 0Alanine Aminotransferase Grade 1Bilirubin Grade 0Bilirubin Grade 1Creatinine Grade 0Creatinine Grade 1
Arm C8122130132142371860094413032

[back to top]

Progression-free Survival (PFS) According to RECIST v1.1, as Assessed by the Investigator

PFS is calculated as 1+ the number of days from the first dose of study drug to disease progression by RECIST, as determined by the investigator or death due to any cause, whichever occurs first. (NCT03397394)
Timeframe: Cycle 1 Day 1 to End of Treatment, up to approximately 10 months

Interventionmonths (Median)
HRD Unknown1.8
HRD Negative1.8
HRD Positive1.4
Overall1.8

[back to top]

Pharmacokinetics - Trough (Cmin) Level Rucaparib Concentrations

Plasma were collected for trough level PK analysis of rucaparib 1 hour before the morning dose on Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1. (NCT03397394)
Timeframe: From Cycle 2 Day 1 to Cycle 4 Day 1, or approximately 2 months

,,,
Interventionng/mL (Mean)
Cycle 2 Day 1Cycle 3 Day 1Cycle 4 Day 1
HRD Negative1927.771331.172058.00
HRD Positive1853.84643.001585.00
HRD Unknown2354.032037.902225.00
Overall2129.701647.332032.73

[back to top]

Objective Response Rate (ORR) Per RECIST Version 1.1

ORR is defined as the proportion of patients with a confirmed response of complete response (CR) or partial response (PR) by RECIST v1.1 as assessed by the investigator. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR), is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. (NCT03397394)
Timeframe: Time from first dose to date of progression, up to approximately 19 months

InterventionParticipants (Count of Participants)
HRD Unknown0
HRD Negative0
HRD Positive0
Overall0

[back to top]

Overall Survival

Overall survival (OS) was defined as time from the date of first dose of rucaparib to the date of death due to any cause. Patients without a known date of death were to be censored on the date the patient was last known to be alive. A Kaplan-Meier analysis of OS was planned, however, due to early study termination and limited duration of OS follow-up, a descriptive summary of total deaths are presented. This includes deaths recorded on study (from first dose of study drug until 28 days after last dose of study drug), and deaths recorded in long-term follow-up (from last dose +28 days until death, loss to follow-up, withdrawal of consent, or study closure). (NCT03397394)
Timeframe: The total study time for reporting of deaths was approximately 19 months.

InterventionParticipants (Count of Participants)
HRD Unknown15
HRD Negative15
HRD Positive9
Overall39

[back to top]

Median Overall Survival

To estimate the median overall survival of patients treated with combination rucaparib and bevacizumab. (NCT03476798)
Timeframe: up to 2 years

InterventionMonths (Median)
Bevacizumab + Rucaparib10.12

[back to top]

Proportion of Patients Who Had Objective Tumor Response

To estimate the proportion of patients treated with bevacizumab and rucaparib who have objective tumor response (complete or partial) (NCT03476798)
Timeframe: up to 2 years

InterventionProportion of patients (Number)
Bevacizumab + Rucaparib0.14

[back to top]

Number of Patients Who Experience Toxicity

To determine the nature and degree of toxicity in combination of rucaparib and bevacizumab (Adverse Event Grade 3 and higher). (NCT03476798)
Timeframe: up to 2 year

InterventionParticipants (Count of Participants)
Bevacizumab + Rucaparib22

[back to top]

Median Progression-free Survival Time

To estimate the progression-free survival (PFS) of patients with persistent or recurrent cervical or endometrial cancer treated with combination rucaparib and bevacizumab Progression for measurable disease per RECIST v1.1 Progression for patients with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry. (NCT03476798)
Timeframe: up to 2 years

InterventionMonths (Median)
Bevacizumab + Rucaparib3.83

[back to top]

Proportion of Patients Who Are Progression-free at 6 Months

"To estimate the proportion of pts treated w/bevacizumab who are progression-free.~Progression for measurable disease per RECIST v1.1. Progression for pts with non-measurable disease at baseline is defined as increasing clinical, radiological, or histological evidence of disease since study entry." (NCT03476798)
Timeframe: 6 months

InterventionProportion of patients (Number)
Bevacizumab + Rucaparib0.29

[back to top]

Percentage of Participants With Dose Limiting Toxicities (DLT) (Phase 1)

Dose limiting toxicities (DLT) is measured by patients with grade 3 or 4 toxicity within 4 weeks of starting leading to discontinuation of rucaparib for at least 1 week (NCT03572478)
Timeframe: 8 weeks

Interventionpercentage of participants (Number)
Combination Therapy (Phase 1 Cohort)50

[back to top]

Percentage of Participants With Adverse Events

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. (NCT03840200)
Timeframe: From Baseline up until 90 days after the last dose of study drug (up to 2 years)

Interventionpercentage of participants (Number)
Dose Escalation-Cohort 1100
Dose Escalation-Cohort 2a100
Dose Escalation-Cohort 2b100
Dose Expansion100

[back to top]

Plasma Concentration of Rucaparib

(NCT03840200)
Timeframe: Cycle 1 Day 15 and Cycle 2 Day 1 and 15: Predose (1 cycle = 28 days)

,,,
Interventionng/mL (Geometric Mean)
Cycle 1 Day 15: PredoseCycle 2 Day 1: PredoseCycle 2 Day 15: Predose
Dose Escalation-Cohort 17756311090
Dose Escalation-Cohort 2a31301660263
Dose Escalation-Cohort 2b99410501250
Dose Expansion16601210975

[back to top]

Percentage of Participants With Objective Response, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1)

Objective response rate (ORR), defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1). A complete response was defined as the disappearance of all lesions. Pathological lymph nodes (whether target or non-target) must have a reduction in short axis to less than 10 millimeters (mm). A partial response was defined as ≥30% decrease in the sum of the diameter of target lesions, in the absence of CR persistence of one or more non-target lesions. The analysis is based on the subset of participants with measurable lesions as per RECIST criteria at baseline. ORR was calculated, and the 95% CI was estimated using the Clopper-Pearson method. (NCT03840200)
Timeframe: From Baseline up to 1.5 years (assessed at the end of Cycle 2,4,6, and every 3 cycles thereafter up to progression, 1 cycle= 28 days)

Interventionpercentage of participants (Number)
Dose Escalation-Cohort 10
Dose Escalation-Cohort 2a0
Dose Escalation-Cohort 2b0
Dose Expansion13.3

[back to top]

Percentage of Participants With Prostate-Specific Antigen Response (PSAR)

PSA response was defined as the percentage of participants with a reduction in the PSA level of 50% or more. PSA response analysis was based on central PSA measurement. The 95% CI was estimated using the Clopper-Pearson method. (NCT03840200)
Timeframe: From Baseline up to 1.5 years

Interventionpercentage of participants (Number)
Dose Escalation-Cohort 10
Dose Escalation-Cohort 2a33.3
Dose Escalation-Cohort 2b25.0
Dose Expansion23.1

[back to top]

Radiographic Progression Free Survival (rPFS), as Assessed by Prostate Cancer Working Group 3 Criteria (PCWG3)

rPFS was defined as the time from study treatment initiation to the first occurrence of documented disease progression, as assessed by the investigator with the use of the PCWG3 criteria (soft tissue: Progressive disease on computed tomography [CT] or MRI scans according to RECIST v1.1, and bone metastasis by bone scan according to the PCWG3 criteria) or death from any cause, whichever occurred first. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and an absolute increase of at least 5 mm, or the presence of new lesions. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT03840200)
Timeframe: From Baseline up to 1.5 years (assessed at the end of Cycle 2,4,6, and every 3 cycles thereafter up to progression, 1 cycle= 28 days)

Interventionmonths (Median)
Dose Escalation-Cohort 111.0
Dose Escalation-Cohort 2a3.0
Dose Escalation-Cohort 2b5.1
Dose Expansion7.2

[back to top]

Plasma Concentration of Ipatasertib

(NCT03840200)
Timeframe: Dose Escalation: Cycle 1: Day 1 and 15 (1, 2 ,3, 5 hours post-dose), Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose); Dose Expansion: Cycle 1: Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose) (1 cycle = 28 days)

Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
Cycle 1 Day 15: PredoseCycle 2 Day 1: PredoseCycle 2 Day 15: Predose
Dose Expansion48.431.248.6

[back to top]

Plasma Concentration of Ipatasertib

(NCT03840200)
Timeframe: Dose Escalation: Cycle 1: Day 1 and 15 (1, 2 ,3, 5 hours post-dose), Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose); Dose Expansion: Cycle 1: Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose) (1 cycle = 28 days)

,,
Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
Cycle 1 Day 1:1 hour post doseCycle 1 Day 1:2 hour post doseCycle 1 Day 1:3 hour post doseCycle 1 Day 1:5 hour post doseCycle 1 Day 15: PredoseCycle 1 Day 15:1 hour post doseCycle 1 Day 15:2 hour post doseCycle 1 Day 15:3hour post doseCycle 1 Day 15:5 hour post doseCycle 2 Day 1: PredoseCycle 2 Day 15: Predose
Dose Escalation-Cohort 116015911693.421.613098.792.485.119.218.9
Dose Escalation-Cohort 2a17213313112739.424217714110520.931.1
Dose Escalation-Cohort 2b19223024917133.515817718117240.149.4

[back to top]

Plasma Concentration of Ipatasertib's Metabolite (G-037720)

(NCT03840200)
Timeframe: Dose Escalation: Cycle 1: Day 1 and 15 (1, 2 ,3, 5 hours post-dose), Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose); Dose Expansion: Cycle 1: Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose) (1 cycle = 28 days)

,,
Interventionng/mL (Geometric Mean)
Cycle 1 Day 1:1 hour post doseCycle 1 Day 1:2 hour post doseCycle 1 Day 1:3 hour post doseCycle 1 Day 1:5 hour post doseCycle 1 Day 15: PredoseCycle 1 Day 15:1 hour post doseCycle 1 Day 15:2 hour post doseCycle 1 Day 15:3 hour post doseCycle 1 Day 15: 5 hour post doseCycle 2 Day 1: PredoseCycle 2 Day 15: Predose
Dose Escalation-Cohort 165.071.257.844.011.838.043.238.533.010.311.3
Dose Escalation-Cohort 2a81.192.785.085.323.767.476.365.853.313.919.7
Dose Escalation-Cohort 2b82.011514111220.256.165.075.973.422.426.4

[back to top]

Plasma Concentration of Ipatasertib's Metabolite (G-037720)

(NCT03840200)
Timeframe: Dose Escalation: Cycle 1: Day 1 and 15 (1, 2 ,3, 5 hours post-dose), Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose); Dose Expansion: Cycle 1: Day 15 (Predose) and Cycle 2: Day 1 and 15 (Predose) (1 cycle = 28 days)

Interventionng/mL (Geometric Mean)
Cycle 1 Day 15: PredoseCycle 2 Day 1: PredoseCycle 2 Day 15: Predose
Dose Expansion25.716.323.6

[back to top]

Overall Survival (OS) in All Participants

OS was defined as the time from study treatment initiation to the time of death due to any cause. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT03840200)
Timeframe: From Baseline to death from any cause, assessed up to 2 years

Interventionmonths (Median)
Dose Escalation-Cohort 120.8
Dose Escalation-Cohort 2a13.8
Dose Escalation-Cohort 2b13.3
Dose ExpansionNA

[back to top]

Duration of Objective Response in Participants With Measurable Disease at Baseline, as Assessed by Investigator Based on RECIST v1.1

DOR was defined as the time from the first occurrence of a documented objective response until the time of documented disease progression or death from any cause during the study, whichever occurred first. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and an absolute increase of at least 5 mm, or the presence of new lesions. The duration of response was estimated by Kaplan-Meier. 95% CI for median was computed using the method of Brookmeyer and Crowley. (NCT03840200)
Timeframe: From Baseline up to 1.5 years (assessed at the end of Cycle 2,4,6, and every 3 cycles thereafter up to progression, 1 cycle= 28 days)

Interventionmonths (Median)
Dose ExpansionNA

[back to top]

Dose Escalation: Percentage of Participants With Dose-Limiting Toxicities (DLTs) That Determine the Maximum-Tolerated Dose (MTD) of the Ipatasertib and Rucaparib Combination

A DLT was defined as adverse events related to study treatments occurring during the DLT reporting period, which included: any death related to study treatment; grade 4 neutropenia lasting for ≥7 days; grade ≥3 neutropenia complicated by fever ≥38°C or infection; grade 4 thrombocytopenia lasting for ≥7 days; grade ≥3 thrombocytopenia complicated by hemorrhage or that requires transfusion; study treatment-related grade ≥3 non-hematologic toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5 (NCI CTCAE, v5.0). (NCT03840200)
Timeframe: Day -7 to Day 28 of Cycle 1 (1 cycle = 28 days) (up to 35 days)

Interventionpercentage of participants (Number)
Dose Escalation-Cohort 112.5
Dose Escalation-Cohort 2a33.3
Dose Escalation-Cohort 2b0

[back to top] [back to top]

Duration of Response (DoR)

Time from date of first documentation of response (complete or partial) to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause among participants who achieve a response. Participants last known to be alive without report of progression are censored at date of last disease assessment. For participants with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan will be used as the date of progression. (NCT03845296)
Timeframe: From date of registration to a maximum of 3 years or death

Interventionmonths (Median)
Cohort 1: SquamousNA
Cohort 2: Non-Squamous14.9

[back to top]

Investigator-Assessed Progression-Free Survival (IA-PFS)

"Time from date of registration to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause. Participants last known to be alive without report of progression are censored at date of last disease assessment. For participants with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) is used as the date of progression.~Progression: One or more of: 20% increase in sum of diameters of target lesions over smallest sum observed and absolute increase of at least 0.5cm; Unequivocal progression of non-measurable disease in opinion of the treating physician; Appearance of any new lesion/site; Death due to disease w/o prior progression or symptomatic deterioration Symptomatic deterioration: Global deterioration of health status requiring treatment discontinuation w/o objective evidence of progression" (NCT03845296)
Timeframe: From date of registration to a maximum of 3 years or death

Interventionmonths (Median)
Cohort 1: Squamous2.9
Cohort 2: Non-Squamous3.5

[back to top]

Overall Response Rate

"Percentage of participants with a complete or partial, confirmed or unconfirmed response.~Complete Response (CR): Complete disappearance of all target and non-target lesions. No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to < 1.0 cm. All disease must be assessed using the same technique as baseline.~Partial Response (PR): Applies only to participants with at least one measurable lesion. Greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. All target measurable lesions must be assessed using the same techniques as baseline." (NCT03845296)
Timeframe: From date of registration to a maximum of 3 years or death

InterventionPercentage of participants (Number)
Cohort 1: Squamous8
Cohort 2: Non-Squamous12

[back to top]

Overall Survival (OS)

Time from date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact. (NCT03845296)
Timeframe: From date of registration to a maximum of 3 years or death

Interventionmonths (Median)
Cohort 1: Squamous8.2
Cohort 2: Non-Squamous7.8

[back to top]

Disease Control Rate

"Disease control rate (DCR) is the number of patients who had either complete response (CR, Disappearance of all target lesions), partial response (PR, >=30% decrease in the sum of the longest diameter of target lesions) or stable disease (SD, less than 30% decrease in the sum of the biggest dimension but no more than 20% increase ) per RECICST 1.0 divided by the total number of patients. DOR= (CR+PR+SD)/Total number on trial x 100%.~The timepoints were combined. The best responses were used in calculating disease control rate" (NCT03958045)
Timeframe: 8 weeks, 16 weeks and 24 weeks post-treatment

Interventionpercentage of participants (Number)
Patients With Stage IV SCLC33.3

[back to top]

Quality of Life Scale Baseline

Quality of life is assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire, which probes function and symptoms. Scores range from 0-100. High scores on functional scales represent a high/healthy level of functioning; high scores symptom scales represent a high level of symptomology. (NCT03958045)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Physical FunctioningRole FunctioningEmotional FunctioningCognitive FunctioningSocial FunctioningGlobal health status
Patients With Stage IV SCLC76.169.378.18172.465.2

[back to top]

Quality of Life Scale at Disease Progression

Quality of life is assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire, which probes function and symptoms. Scores range from 0-100. High scores on functional scales represent a high/healthy level of functioning; high scores symptom scales represent a high level of symptomology. (NCT03958045)
Timeframe: Disease Progression up to 2 years

Interventionunits on a scale (Mean)
Physical FunctioningRole FunctioningEmotional FunctioningCognitive FunctioningSocial FunctioningGlobal health status
Patients With Stage IV SCLC66.741.745.841.75050

[back to top]

Quality of Life Scale 4 Months

Quality of life is assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire, which probes function and symptoms. Scores range from 0-100. High scores on functional scales represent a high/healthy level of functioning; high scores symptom scales represent a high level of symptomology. (NCT03958045)
Timeframe: 4 months

Interventionunits on a scale (Mean)
Physical FunctioningRole FunctioningEmotional FunctioningCognitive FunctioningSocial FunctioningGlobal health status
Patients With Stage IV SCLC70.56575.678.373.365.8

[back to top]

Objective Response Rate

"Objective response rate (ORR) is the proportion of patients with complete response or partial response according to RECIST v1.1. Patients with complete response at baseline will be excluded from ORR analysis.~The timepoints were combined. The best responses were used in calculating objective response rate" (NCT03958045)
Timeframe: 8 weeks, 16 weeks and 24 weeks post-treatment

InterventionParticipants (Count of Participants)
Patients With Stage IV SCLC4

[back to top]

Progression Free Survival

"Duration (time) of progression-free survival after response to initial platinum-based therapy.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions from starting maintenance treatment" (NCT03958045)
Timeframe: 0-2 years

Interventionmonths (Median)
Patients With Stage IV SCLC11

[back to top]

Overall Survival

Percentage of surviving participants at 1 and 2 years (NCT03958045)
Timeframe: 0-2 years

Interventionpercentage of participants (Number)
1 year2 years
Patients With Stage IV SCLC93.5552.82

[back to top]

Best Overall Response Rate by Investigator

Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in participants with advanced prostate cancer). (NCT04171700)
Timeframe: From first dose of study drug until disease progression (up to approximately 2 years)

InterventionParticipants (Count of Participants)
Rucaparib Cohort A9
Rucaparib Cohort B2

[back to top]

Duration of Response

Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression. (NCT04171700)
Timeframe: From first dose of study drug until disease progression (up to approximately 2 years)

Interventionmonth (Median)
Rucaparib Cohort A4.1
Rucaparib Cohort B6.8

[back to top]

Progression-free Survival

Measure of clinical benefit, defined as the duration from study enrollment to objective tumor progression. Progression was defined using RECIST v1.1, as a 20% increase in the sum of diameters of target lesions (and an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or the appearance of new lesions. For mCRPC disease, the PCWG3 confirmed bone disease progression criteria (2+2) were also incorporated. (NCT04171700)
Timeframe: From first dose of study drug until disease progression (up to approximately 2 years)

Interventionmonth (Median)
Rucaparib Cohort A3.7
Rucaparib Cohort B3.6

[back to top]

Number of Participants Experiencing Treatment-emergent Adverse Events

(NCT04171700)
Timeframe: From first dose of study drug until disease progression (up to approximately 2 years)

InterventionParticipants (Count of Participants)
Rucaparib Cohort A63
Rucaparib Cohort B20

[back to top]

Disease Control Rate

Measure of clinical benefit, defined as the percentage of complete response (CR), partial response (PR), and stable disease (SD) beyond 16 weeks. (NCT04171700)
Timeframe: From first dose of study drug until disease progression (up to approximately 2 years)

Interventionpercentage of participants (Number)
Rucaparib Cohort A36.1
Rucaparib Cohort B25.0

[back to top]

Overall Survival

Measure of clinical benefit, defined as the duration from study enrollment to death. (NCT04171700)
Timeframe: From first dose of study drug until disease progression (up to approximately 2 years)

Interventionmonth (Median)
Rucaparib Cohort A13.3
Rucaparib Cohort B8.0

[back to top]

Evaluate the PK of Rucaparib in Combination With Other Anticancer Agents for mCRPC.

Cmin of rucaparib and its metabolite. Rucaparib only run-in Cmin includes run-in D6, D7 and Cycle 1 D1. All of these samples were collected following rucaparib monotherapy. Rucaparib and other anticancer agent Combination Cmin includes Cycle 1 (D8, D15, and D22). (NCT04179396)
Timeframe: 1 week rucaparib only run-in and 1 cycle (28 days) of combination treatment

Interventionng/ml (Mean)
Cmin of rucaparib during 1-week rucaparib only run-inCmin of rucaparib metabolite M324 during 1-week rucaparib only run-inCmin of rucaparib during 1st cycle of rucaparib enzalutamide combo treatmentCmin of rucaparib metabolite M324 during 1st cycle of rucaparib enzalutamide combo treatment
Arm A: Oral Rucaparib and Enzalutamide13452331558311

[back to top]

Incidence of Dose-Limiting Toxicities (DLTs) in Participants Taking Rucaparib in Combination With Other Anticancer Agents for mCRPC

A DLT is defined according to criteria specified in the protocol and assessed by the investigator, based on toxicity grade (according to the NCI CTCAE v5.0), clinical significance, and possible relationship to the study drug combination. The toxicity cannot be a recognized adverse effect of enzalutamide, abiraterone or prednisone/prednisolone and/or attributable to mCRPC or mCRPC-related processes under investigation. (NCT04179396)
Timeframe: First 2 cycles of rucaparib combination treatment (56 days) for Arm A

InterventionParticipants (Count of Participants)
Arm A: Oral Rucaparib and Enzalutamide0
Arm B: Oral Rucaparib and Abiraterone0

[back to top]